<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" specific-use="sps-1.8" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="publisher-id">visa</journal-id>
			<journal-title-group>
				<journal-title>Vigilância Sanitária em Debate: Sociedade, Ciência &amp; Tecnologia</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Vigilância Sanitária em Debate</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="epub">2317-269X</issn>
			<publisher>
				<publisher-name>INCQS-FIOCRUZ</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="publisher-id">00004</article-id>
			<article-id pub-id-type="doi">10.22239/2317-269X.01938</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>ARTICLE</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>One year of COVID-19 pandemic: Epidemiological characteristics of COVID-19 in the city of Uberaba, Minas Gerais, Brazil</article-title>
				<trans-title-group xml:lang="pt">
					<trans-title>Um ano da pandemia de COVID-19: características epidemiológicas da COVID-19 na cidade de Uberaba, Minas Gerais, Brasil</trans-title>
				</trans-title-group>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-8822-5508</contrib-id>
					<name>
						<surname>Maldonado</surname>
						<given-names>Michelli</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>I</sup></xref>
					<xref ref-type="corresp" rid="c01"><sup>*</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-4860-309X</contrib-id>
					<name>
						<surname>Oliveira</surname>
						<given-names>Ronaldo Junio de</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-8223-805X</contrib-id>
					<name>
						<surname>Cintra</surname>
						<given-names>Mariangela Torreglosa Ruiz</given-names>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>III</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>I</label>
				<institution content-type="orgdiv1">Instituto de Ciências Exatas, Naturais e Educação</institution>
				<institution content-type="normalized">Universidade Federal do Triângulo Mineiro</institution>
				<institution content-type="orgname">Universidade Federal do Triângulo Mineiro</institution>
				<addr-line>
					<named-content content-type="city">Uberaba</named-content>
					<named-content content-type="state">MG</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Departamento de Matemática, Instituto de Ciências Exatas, Naturais e Educação , Universidade Federal do Triângulo Mineiro (UFTM), Uberaba , MG , Brasil </institution>
				<email>michelli.oliveira@uftm.edu.br</email>
			</aff>
			<aff id="aff2">
				<label>II</label>
				<institution content-type="orgdiv2">Laboratório de Biofísica Teórica</institution>
				<institution content-type="orgdiv1">Departamento de Física</institution>
				<institution content-type="normalized">Universidade Federal do Triângulo Mineiro</institution>
				<institution content-type="orgname">Universidade Federal do Triângulo Mineiro</institution>
				<addr-line>
					<named-content content-type="city">Uberaba</named-content>
					<named-content content-type="state">MG</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Laboratório de Biofísica Teórica , Departamento de Física , Universidade Federal do Triângulo Mineiro (UFTM), Uberaba , MG , Brasil </institution>
			</aff>
			<aff id="aff3">
				<label>III</label>
				<institution content-type="orgdiv1">Departamento de Ciências Biológicas</institution>
				<institution content-type="normalized">Universidade Federal do Triângulo Mineiro</institution>
				<institution content-type="orgname">Universidade Federal do Triângulo Mineiro</institution>
				<addr-line>
					<named-content content-type="city">Uberaba</named-content>
					<named-content content-type="state">MG</named-content>
				</addr-line>
				<country country="BR">Brasil</country>
				<institution content-type="original"> Departamento de Ciências Biológicas , Universidade Federal do Triângulo Mineiro (UFTM), Uberaba , MG , Brasil </institution>
			</aff>
			<author-notes>
				<corresp id="c01">
					<label>*</label> E-mail: <email>michelli.oliveira@uftm.edu.br</email>
				</corresp>
				<fn fn-type="other">
					<p>Authors’ Contribution</p>
					<p>Maldonado M - Conception, planning (study design), acquisition, analysis, interpretation of results and writing of the work. Oliveira RJ, Cintra MTR - Conception, planning (study design) and writing of the work. All authors approved the final version of the work.</p>
				</fn>
				<fn fn-type="conflict">
					<p>Conflict of Interest</p>
					<p>Authors have no potential conflict of interest to declare, related to this study’s political or financial peers and institutions.</p>
				</fn>
			</author-notes>
			<!--<pub-date date-type="pub" publication-format="electronic">
				<day>06</day>
				<month>01</month>
				<year>2024</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic">
				<season>Apr-Jun</season>
				<year>2022</year>
			</pub-date>-->
			<pub-date pub-type="epub-ppub">
				<season>Apr-Jun</season>
				<year>2022</year>
			</pub-date>
			<volume>10</volume>
			<issue>2</issue>
			<fpage>23</fpage>
			<lpage>32</lpage>
			<history>
				<date date-type="received">
					<day>07</day>
					<month>06</month>
					<year>2021</year>
				</date>
				<date date-type="accepted">
					<day>02</day>
					<month>05</month>
					<year>2022</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
					<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
				</license>
			</permissions>
			<abstract>
				<title>ABSTRACT</title>
				<sec>
					<title>Introduction</title>
					<p>The new coronavirus pandemic (COVID-19) is unprecedented in recorded human history. It spread from Wuhan, China, in early December, 2019, crossing the entire planet and reaching Brazilian shores in the following February. It was declared a pandemic on March 11, 2020, with the first case recorded in the city of Uberaba, state of Minas Gerais, Brazil, on March 18, 2020. Since then, we have been collecting data and assessing the evolution of this fatal disease.</p>
				</sec>
				<sec>
					<title>Objective</title>
					<p>In this work, we report the epidemiological characteristics of one year of the COVID-19 in Uberaba, and discuss its implications to the general public.</p>
				</sec>
				<sec>
					<title>Method</title>
					<p>This is an observational, descriptive, documentary and retrospective study to describe the epidemiological profile of COVID-19 cases in the city of Uberaba from March 18, 2020 to March 17, 2021.</p>
				</sec>
				<sec>
					<title>Results</title>
					<p>The study shows that the young-working age population are those who most spread the virus; however, the elderly are those who suffer and die the most, with slight differences regarding sex. This is in line with the reported national and international epidemiological profiles that show a shifting tendency of younger generations to be increasingly active on the evolution of the pandemic. We observed two major peaks on the two epidemiological time-series, confirmed cases and deaths, with an average age of 41 years old for the confirmed cases and 68 for the confirmed deaths. It was also reported that the lethality rate was 2.45%, and 80.00% of the confirmed deaths suffered from some previous health condition.</p>
				</sec>
				<sec>
					<title>Conclusions</title>
					<p>In this sense, a permanent epidemiological surveillance has to take place in order to guide public health counter-measurements. The epidemiological characteristics of COVID-19 in Uberaba and related analyses are reported in the online observatory at https://coviduberaba.github.io.</p>
				</sec>
			</abstract>
			<trans-abstract xml:lang="pt">
				<title>RESUMO</title>
				<sec>
					<title>Introdução</title>
					<p> A pandemia do novo coronavírus (COVID-19) é inédita na história humana registrada. Espalhou-se de Wuhan, na China, no início de dezembro de 2019, cruzando todo o planeta e chegando à costa brasileira no mês de fevereiro seguinte. Foi declarada pandemia em 11 de março de 2020, com o primeiro caso registrado na cidade de Uberaba, estado de Minas Gerais, Brasil, em 18 de março de 2020. Desde então, estamos coletando dados e avaliando a evolução dessa fatalidade doença.</p>
				</sec>
				<sec>
					<title>Objetivo</title>
					<p> Neste trabalho, relatamos as características epidemiológicas de um ano da COVID-19 em Uberaba e discutimos suas implicações para o público em geral.</p>
				</sec>
				<sec>
					<title>Método</title>
					<p> Trata-se de um estudo observacional, descritivo, documental e retrospectivo para descrever o perfil epidemiológico dos casos de COVID-19 na cidade de Uberaba no período de 18 de março de 2020 até 17 de março de 2021.</p>
				</sec>
				<sec>
					<title>Resultados</title>
					<p> O estudo mostra que a população jovem em idade ativa é a que mais espalha o vírus, no entanto, os idosos são os que mais sofrem e morrem, com pequenas diferenças em relação ao sexo. Isso está de acordo com os perfis epidemiológicos nacionais e internacionais relatados que mostram uma tendência de mudança das gerações mais jovens a serem cada vez mais ativas na evolução da pandemia. Observamos dois grandes picos nas duas séries temporais epidemiológicas, casos confirmados e óbitos, com média de idade de 41 anos para os casos confirmados e 68 para os óbitos confirmados. Também foi relatado que a taxa de letalidade foi de 2,45%, e 80,00% das mortes confirmadas sofriam de alguma condição de saúde anterior.</p>
				</sec>
				<sec>
					<title>Conclusões</title>
					<p> Nesse sentido, uma vigilância epidemiológica permanente deve ocorrer para orientar as contramedidas de saúde pública. As características epidemiológicas da COVID-19 em Uberaba e análises relacionadas são relatadas no observatório <italic>online</italic> em https://coviduberaba.github.io.</p>
				</sec>
			</trans-abstract>
			<kwd-group xml:lang="en">
				<kwd>COVID-19</kwd>
				<kwd>Epidemiological Characteristics</kwd>
				<kwd>Surveillance</kwd>
				<kwd>Statistical Analysis</kwd>
				<kwd>Coronavirus</kwd>
				<kwd>Public Health</kwd>
			</kwd-group>
			<kwd-group xml:lang="pt">
				<kwd>COVID-19</kwd>
				<kwd>Característica Epidemiológicas</kwd>
				<kwd>Vigilância</kwd>
				<kwd>Análise Estatística</kwd>
				<kwd>Coronavírus</kwd>
				<kwd>Saúde Pública</kwd>
			</kwd-group>
			<funding-group>
				<award-group>
					<funding-source>FAPEMIG</funding-source>
					<award-id>APQ-00941-14</award-id>
				</award-group>
				<award-group>
					<funding-source>CNPq</funding-source>
					<award-id>438316/2018-5</award-id>
				</award-group>
				<award-group>
					<funding-source>CNPq</funding-source>
					<award-id>312328/2019-2</award-id>
				</award-group>
				<award-group>
					<funding-source>PROPPG</funding-source>
					<award-id>30/2018</award-id>
				</award-group>
			</funding-group>
			<counts>
				<fig-count count="5"/>
				<table-count count="0"/>
				<equation-count count="0"/>
				<ref-count count="47"/>
				<page-count count="10"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<sec sec-type="intro">
			<title>INTRODUCTION</title>
			<p>Coronaviruses are positive‐stranded RNA viruses that taxonomically come under the family Coronaviridae and subfamily Coronavirinae, which can be divided into four genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus. In their structure, they are enveloped viruses with a positive‐sense single‐stranded RNA genome having spherical, oval or pleomorphic shape. Viruses from this family may infect a wide variety of hosts, producing symptoms and diseases that can be mild, moderate or fatal, such as the Severe Acute Respiratory Syndrome (SARS), caused by the SARS-CoV, and the Middle East Respiratory Syndrome (MERS), caused by MERS-CoV. The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) belongs to genus Betacoronavirus <sup><xref ref-type="bibr" rid="B1">1</xref> , <xref ref-type="bibr" rid="B2">2</xref></sup> .</p>
			<p>The SARS-CoV-2, baptized by the International Committee on Taxonomy of Viruses (ICTV), contains higher conserved sequences in open reading frame (ORF) 1a/1b. SARS-CoV-2 infects humans, and it is the etiologic agent of the Coronavirus Disease 2019 (COVID-19) <sup><xref ref-type="bibr" rid="B1">1</xref> , <xref ref-type="bibr" rid="B2">2</xref></sup> . The structure of SARS‐CoV‐2 contains a positive‐sense single‐stranded RNA genome packed in the virus membrane envelope. The ORF1a is the longest ORF that occupies almost two thirds of the genome. The ORF1b overlaps with ORF1a following shorter subgRNAs (sgRNA) that encodes four structural proteins, spike (S), membrane (M), envelope (E) and nucleocapsid (N), in addition to others accessory proteins. The M protein promotes membrane curvature that helps to bind the nucleocapsid. Protein E executes an important role in viral pathogenesis. The N protein assembles two domains that are able to bind the viral RNA genome by different mechanisms. N protein also interacts with nsp3, helping to pack and to encapsulate the genome structure inside the virions. The SARS-CoV-2 virus surface possesses S proteins that play pivotal roles in viral attachment, fusion and entry, establishing a hot spot to the development of therapeutics against the virus. SARS-CoV-2 S protein includes the receptor binding domain (RBD), known to interact strongly with the receptor angiotensin converting enzyme 2 (ACE2) <sup><xref ref-type="bibr" rid="B2">2</xref> , <xref ref-type="bibr" rid="B3">3</xref> , <xref ref-type="bibr" rid="B4">4</xref></sup> .</p>
			<p>On March 11, 2020, the outbreak of COVID-19 was elevated to a pandemic status by the World Health Organization (WHO), meaning that the disease affects several different countries <sup><xref ref-type="bibr" rid="B5">5</xref></sup> . The first case was described in the Chinese city of Wuhan on December 1, 2019. In Brazil, the first case was reported on February 25, 2020, in the city of São Paulo, whereas the first case in Uberaba was reported on March 18, 2020 <sup><xref ref-type="bibr" rid="B6">6</xref></sup> .</p>
			<p>The high transmission of SARS-CoV-2 has caused a greater absolute number of deaths than the combination of the epidemics caused by SARS-CoV and MERS-CoV. By the end of this work, at the end of October, Brazil had a lethality rate of 2.8%, a mortality rate of 289 per 100,000 inhabitants <sup><xref ref-type="bibr" rid="B6">6</xref></sup> . The epidemiological data of individuals infected by the virus, as analyzed in a Brazilian study, showed a number of 514,200 patients in the period ranging from February 25 to May 31 of 2020. Patients were predominantly male, with an average age of 59 years. The death rate was approximately 5.7% and 83.7% of these individuals confirmed with COVID-19 showed at least one medical condition: 66.5% had cardiovascular disease and 54.5% had diabetes <sup><xref ref-type="bibr" rid="B7">7</xref></sup> .</p>
			<p>Several studies have been carried out in Brazil with the aim of evaluating the incidence and prevalence of COVID-19 in states such as Ceará <sup><xref ref-type="bibr" rid="B8">8</xref> , <xref ref-type="bibr" rid="B9">9</xref></sup> , Roraima <sup><xref ref-type="bibr" rid="B10">10</xref></sup> , Paraná <sup><xref ref-type="bibr" rid="B11">11</xref></sup> , regions such as the Ribeira Valley <sup><xref ref-type="bibr" rid="B12">12</xref></sup> , Amazônia <sup><xref ref-type="bibr" rid="B13">13</xref></sup> , South <sup><xref ref-type="bibr" rid="B14">14</xref></sup> and Brazilian municipalities such as Uberlândia <sup><xref ref-type="bibr" rid="B15">15</xref></sup> and Patos de Minas, in the State of Minas Gerais <sup><xref ref-type="bibr" rid="B16">16</xref></sup> , and Teixeira de Freitas in Bahia <sup><xref ref-type="bibr" rid="B17">17</xref></sup> .</p>
			<p>Uberaba, a city in the Triângulo Mineiro, has a land area of 4,539.57 km <sup><xref ref-type="bibr" rid="B2">2</xref></sup> and an estimated population of 340,277 people <sup><xref ref-type="bibr" rid="B18">18</xref></sup> . Isolation measures in the city of Uberaba began on March 18, 2020, with the suspension of surgical services, attendance in clinics and other areas related to health. Soon after, the isolation measures took greater proportions, with the closing of commercial establishments, leisure places and restaurants, leaving only services considered essential, such as supermarkets, pharmacies and hospitals open. Establishments were allowed to reopen with mandatory protective measures, such as social distancing, hygiene, and mandatory use of masks in May 2020. By the end of 2020, a decree prevented the operation of in-person teaching networks, restaurants, gyms, parties and the like <sup><xref ref-type="bibr" rid="B19">19</xref></sup> .</p>
			<p>With the continuous unfolding of the pandemic, the COVID-19 Observatory - Uberaba <sup><xref ref-type="bibr" rid="B20">20</xref></sup> was created – an initiative by researchers from the Federal University of Triangulo Mineiro (UFTM) in partnership with the Uberaba City Hall. The group presents weekly reports with information about the epidemiology of the disease, helping to provide the population with safe information via website (https://coviduberaba.github.io) and contributing to raise awareness about the situation.</p>
			<p>Given that, this work aimed to outline an epidemiological profile and to understand the dynamics of the disease in the city of Uberaba.</p>
		</sec>
		<sec sec-type="methods">
			<title>METHOD</title>
			<sec>
				<title>Study region</title>
				<p>The city of Uberaba is a Brazilian municipality located in the Triângulo Mineiro region of the State of Minas Gerais (MG). According to the Brazilian Institute of Geography and Statistics (IBGE), the estimated population of Uberaba in 2020 is 340,277 inhabitants, of which 48.8% are male and 51.2% are female <sup><xref ref-type="bibr" rid="B18">18</xref></sup> .</p>
			</sec>
			<sec>
				<title>Data collection</title>
				<p>This is an observational, descriptive, documentary and retrospective study to describe the epidemiological profile of COVID-19 cases in the city of Uberaba from March 18, 2020 to March 17, 2021. The variables analyzed were: number of cases and deaths by epidemiological weeks, sex and age range of confirmed cases, sex and age range of confirmed deaths and previous indication of medical conditions in the confirmed deaths. Data were organized, tabulated and analyzed using the software Microsoft <sup>®</sup> Excel version 2000 and the software R-Project 4.0 version 2016 (https://www.r-project.org).</p>
			</sec>
			<sec>
				<title>Ethics statement</title>
				<p>Strict ethical and professional aspects were followed, maintained, and respected as set by the National Health Council in the Resolution nº 466 of December 12, 2012. The resolution recommends that research involving only secondary data from public domain, without nominal identification of the research participants, does not require analysis by the Research Ethics Committees.</p>
			</sec>
			<sec>
				<title>Statistical analysis</title>
				<p>Data were compiled and tabulated to determine simple frequencies (n), relative frequencies (%), means and standard deviation (±). Results are presented in contingency tables and graphs.</p>
			</sec>
		</sec>
		<sec sec-type="results">
			<title>RESULTS</title>
			<p>The study presents an analysis of reported cases of COVID-19 in the city of Uberaba, state of MG, Brazil, during one year of the pandemic. The first reported case was on March 18, 2020 and, by March 17, 2021 the city accounted for 17,254 reported cases of people infected by the new coronavirus. The first peak in the city occurred on September 21, 2020, with a moving average of daily cases of 107 cases. After this date, the moving average of daily cases started to decelerate, returning to break records in the second wave that started in the first half of January 2021, with 120 daily cases reported in the moving average and a new peak on March 10, 2021, with a moving average of daily cases of 129 cases.</p>
			<p>
				<xref ref-type="fig" rid="f01">Figure 1</xref> shows the frequency of reported cases of COVID-19 by epidemiological weeks. The first peak occurred in epidemiological week number 38 (S38) in the year 2020, with 735 cases, while the second peak, in the studied period, was in S10 in the 2021, with 885 cases. This represents a 20.00% increase of the reported cases. In addition, the city reported 9,741 cases in the year 2020. Until March 17, 2021, the city already had 7,513 cases, which represents 77.00% of the total of the previous year.</p>
			<p>
				<fig id="f01">
					<label>Figure 1</label>
					<caption>
						<title>Total number of confirmed cases organized by epidemiological weeks in the city of Uberaba, state of Minas Gerais (MG), Brazil, during one year of the pandemic, from March 18, 2020, to March 17, 2021.</title>
					</caption>
					<graphic xlink:href="f1.jpg"/>
					<attrib>Source: Elaborated by the authors, 2021.</attrib>
				</fig>
			</p>
			<p>Considering the sex variable, in <xref ref-type="fig" rid="f02">Figure 2(a)</xref> 51.69% of the reported cases of COVID-19 were female, whereas 48.31% were male. The female group was, on average, older (41.64 years ± 16.97) than the male group (40.67 years ± 16.27). <xref ref-type="fig" rid="f02">Figure 2(b)</xref> shows, in green, the relative frequency of reported cases of COVID-19 by age group in the city of Uberaba from March 18, 2020, to March 17, 2021. The most affected age group was the one ranging from 30 to 39 years, with 25.83% of total cases. The 20 to 49 age group accounts for 64.75% of the reported cases of COVID-19 in Uberaba. The average age of the total number of cases was 41 years ± 16.64.</p>
			<p>
				<fig id="f02">
					<label>Figure 2</label>
					<caption>
						<title>Total number of confirmed cases organized by the groups gender (2a) and gender (2b) in the city of Uberaba, state of Minas Gerais (MG), Brazil, during one year of the pandemic, from March 18, 2020, to March 17, 2021.</title>
					</caption>
					<graphic xlink:href="f2.jpg"/>
					<attrib>Source: Elaborated by the authors, 2021.</attrib>
				</fig>
			</p>
			<p>COVID-related deaths were also investigated and can be visualized in <xref ref-type="fig" rid="f03">Figure 3</xref> according to the epidemiological weeks. The first peak occurred in S41 in the year 2020 with 12 deaths, while the second peak appeared in S11 in the year 2021 with 38 deaths. This represents a 216.00% increase. The record in confirmed daily deaths was registered in March 2021, with ten reported deaths. <xref ref-type="fig" rid="f04">Figure 4(a)</xref> shows that the average age of confirmed deaths was 68.85 years (± 15.68). <xref ref-type="fig" rid="f04">Figure 4(b)</xref> shows the relative frequency of reported deaths of COVID-19 in the city of Uberaba grouped by age. As of March 17, 424 deaths were reported, indicating a general lethality rate of 2.45%. The minimum age was one year and the highest age was 103 years. 75.00% of the deceased were older than 59. <xref ref-type="fig" rid="f04">Figure 4(b)</xref> indicates that the age group that stands out is the one from 70 to 79 years, 26.18%.</p>
			<p>
				<fig id="f03">
					<label>Figure 3</label>
					<caption>
						<title>Total number of confirmed deaths organized by epidemiological weeks in the city of Uberaba, state of Minas Gerais (MG), Brazil, during one year of the pandemic, from March 18, 2020 to March 17, 2021.</title>
					</caption>
					<graphic xlink:href="f3.jpg"/>
					<attrib>Source: Elaborated by the authors, 2021.</attrib>
				</fig>
			</p>
			<p>
				<fig id="f04">
					<label>Figure 4</label>
					<caption>
						<title>Total number of confirmed deaths organized by the groups age and gender in the city of Uberaba, state of Minas Gerais (MG), Brazil, during one year of the pandemic, from March 18, 2020, to March 17, 2021.</title>
					</caption>
					<graphic xlink:href="f4.jpg"/>
					<attrib>Source: Elaborated by the authors, 2021.</attrib>
				</fig>
			</p>
			<p>It is possible to analyze the lethality degree of the new coronavirus by age group. <xref ref-type="fig" rid="f02">Figure 2(b)</xref> , in purple, also compares confirmed deaths with reported cases of COVID-19 by age group of affected population. The younger age population shows the highest incidence of cases, yet with a very low lethality rate. The highest lethality was found in the age group of 90 years or older, with 34.62% of deaths among the reported cases from this age group, as shown in Figure 4(b) . Most deaths were from the male sex (57.78%). The lethality rate among men was 2.93%, whereas among women, the rate was 2.00%. The females showing higher average age (71.41 years ± 15.92) than male (67.00 years ± 15.30).</p>
			<p>Medical conditions of the deceased were also analyzed and organized in <xref ref-type="fig" rid="f05">Figure 5(a)</xref> . According to the frequency of diagnosis, the prevailing medical conditions were: hypertension (39.00%), heart disease (21.43%), diabetes (21.43%), obesity (8.30%) and other medical conditions (18.15%), as indicated in <xref ref-type="fig" rid="f05">Figure 5(a)</xref> . The mean age of the group with no comorbidities who died was lower (61.90 years ± 17.01) than the group that reported having medical conditions (70.58 years ± 14.86).</p>
			<p>
				<xref ref-type="fig" rid="f05">Figure 5(b)</xref> groups the number of comorbidities in individuals who died from coronavirus. In relation to 424 deaths, 85 (20.04%) did not indicate any previous comorbidities. Among these, 32.94% were female and 67.05% were male.</p>
		</sec>
		<sec sec-type="discussion">
			<title>DISCUSSION</title>
			<p>This study traced the epidemiological profile of the city of Uberaba-MG in the first year of the COVID-19 pandemic. The results of this epidemiological investigation indicate a greater involvement of females, aged between 20 and 49 years. Regarding deaths, there is a higher mortality rate in males, aged over 60 years, with a history of hypertension, heart disease, diabetes, obesity, among others.</p>
			<p>With respect to contamination, our results show that the most affected age group is the 30–39-year age category, and the most affected sex – despite the slight difference – is the female one. On average, the age of the infected individuals is 41 and females were older than males. That is, infected men are younger than women.</p>
			<p>With respect to deaths, the occurrence is more frequent in individuals over 60, with at least one medical condition. The lethality rate for men is 1.5 times higher than that of women, and men were, on average, younger than women. Men dying from COVID-19 are younger and have fewer medical conditions compared to women.</p>
			<p>As of March 17, 2021, the COVID-19 pandemic in Uberaba resulted in 17,254 reported cases, with a peak of 129 cases on March 10, 2021. It is observed that the total number of cases in 2021 until March 17, in just eleven weeks, represents more than 77.00% of the total cases in 2020. The biggest peak of the second wave in the city of Uberaba happened in epidemiological week number 20, in mid-June, with more than 1,300 cases per week <sup><xref ref-type="bibr" rid="B20">20</xref></sup> . The difference in the total number of cases from the first peak to the second, in the period studied and throughout the rest of the year, is explained by the new variants that emerged in the country that contributed to the increase in the incidence of cases and deaths <sup><xref ref-type="bibr" rid="B21">21</xref></sup> . The disease was also responsible for 424 deaths in the city, of which 42.60% were notified in the period studied in 2021, coinciding again with the emergence of new variants.</p>
			<p>The first peak of reported cases in Brazil occurred on July 29, 2020 <sup><xref ref-type="bibr" rid="B6">6</xref></sup> , and a possible explanation to this difference relates to the fact that the pandemic started in the Brazilian capitals, mainly those with international airports. Based on the sequencing and analysis of viral genomes, another Brazilian study showed that there were more than 100 international entries of the virus in Brazil, mainly from European countries. During the initial stage of the pandemic, capitals with international airports suffered the first peaks of the disease, progressively spreading to interior regions such as the Triângulo Mineiro.</p>
			<p>Our study also revealed that the 20–49-year age category gathered the highest number of contaminated individuals. On average, they were 41 years old. These data are in accordance with studies carried out in Pakistan, where contaminated individuals were, on average, 47 years old, with the 20–69 age category showing a higher frequency of infections <sup><xref ref-type="bibr" rid="B22">22</xref></sup> . Similar results were observed in one of the first descriptions of the epidemiological characteristics in Wuhan, with a mean age of 49 years old <sup><xref ref-type="bibr" rid="B23">23</xref></sup> and Australia, mean age of 37 <sup><xref ref-type="bibr" rid="B24">24</xref></sup> . National studies also came to the same conclusions with the example of Macapá <sup><xref ref-type="bibr" rid="B25">25</xref></sup> , with a mean age of 40 years old, and the state of Santa Catarina <sup><xref ref-type="bibr" rid="B26">26</xref></sup> , with the same age group revealed as the most affected one. This scenario can also be explained by the risk factors to which this group is exposed, such as professional occupations, lifestyle, absence of comorbidities or use of medications, which may reflect social and cultural factors <sup><xref ref-type="bibr" rid="B27">27</xref></sup> . Possible genetic explanations will be necessary to complete the interaction of age, sex and risk factors <sup><xref ref-type="bibr" rid="B28">28</xref></sup> .</p>
			<p>With respect to the biological sex of reported cases, our study shows that, although subtle, there are differences both in the frequencies of man and women and in the rate of incidence between the sexes. Women stand out in this phase of the study, a result that differs from the investigation that analyzes the pandemic in Brazil and reveals that 57.00% of those affected are men <sup><xref ref-type="bibr" rid="B7">7</xref></sup> . However, the frequency of infected men (49.10%) and women (50.90%) is identical to the results presented in January 2021 in Southeast Asia and the Western Mediterranean and is also close to African frequencies (47.00% and 53.00%, respectively) <sup><xref ref-type="bibr" rid="B29">29</xref></sup> . The statistical analysis of the data supports that there is a relationship between age and biological sex, and that infected women are older than men <sup><xref ref-type="bibr" rid="B20">20</xref></sup> .</p>
			<p>Our data revealed that until March 17,2021, 305 deaths from COVID-19 were registered, indicating a general lethality rate of 2.45%. the mortality rate in Uberaba is higher than the average mortality rate in Brazil (2.45, Uberaba, 2.40, Brazil) <sup><xref ref-type="bibr" rid="B6">6</xref></sup> , and that of the state of Minas Gerais - 2.09%, considering the same period of study <sup><xref ref-type="bibr" rid="B30">30</xref></sup> .</p>
			<p>The median age of the individuals who died in the city was 71 years old, most of them were older than 60 and the age category with the highest lethality was that of 90 years old or over. This age pattern found in Uberaba relates with data found in the USA, where 80.00% of the deceased were elderly patients aged 65 or older, and patients aged 85 <sup><xref ref-type="bibr" rid="B31">31</xref></sup> . Also, in national studies such as the one in the state of Macapá <sup><xref ref-type="bibr" rid="B13">13</xref></sup> , the highest lethality rate was observed in elderly people older than 70. One of the possible explanations is that, in general, infections in older people are atypical and some factors may contribute to the high incidence of death, such as physiological changes caused by the aging process, medical conditions and use of various medications. Advanced age, therefore, is considered the main risk factor for complications of COVID-19 <sup><xref ref-type="bibr" rid="B31">31</xref></sup> . The senescence also affects immune cells, and features of immunosenescence characterized by decreased native T-cells, increased memory T-cells, and poor response to newly encountered antigens <sup><xref ref-type="bibr" rid="B32">32</xref></sup> .</p>
			<p>In addition to the age factor, some investigations reveal that the biological sex may be associated with the increase in deaths from COVID-19 <sup><xref ref-type="bibr" rid="B33">33</xref></sup> . In our study, most deaths are from the male sex. Investigations conducted in China, South Korea, USA and Italy showed a higher death rate in male patients <sup><xref ref-type="bibr" rid="B22">22</xref> , <xref ref-type="bibr" rid="B34">34</xref> , <xref ref-type="bibr" rid="B35">35</xref></sup> . This difference between sexes may be due to a combination of biological factors, such as differences in chromosomal composition, reproductive organs and sex-related hormones. Gender-specific factors may also play a role, such as behavioral differences (smoking and drinking habits) and many medical conditions which are more frequent in men <sup><xref ref-type="bibr" rid="B28">28</xref> , <xref ref-type="bibr" rid="B36">36</xref></sup> .</p>
			<p>Regarding the chromosome difference, human females have two X chromosomes, while human males have just one. It is known that the process of X-inactivation in women occurs so that, physiologically, there can be dosage compensation. However, 15% to 20% of the genes escape from inactivation in humans, resulting in a higher number of copies in women than in men <sup><xref ref-type="bibr" rid="B37">37</xref> , <xref ref-type="bibr" rid="B38">38</xref></sup> . Hence, as the X chromosome encodes some genes related to immune responses, women have a lower level of viral load and less inflammation compared to men <sup><xref ref-type="bibr" rid="B38">38</xref></sup> . Our data showed no difference between contamination of men and women, yet it is documented that women have stronger innate and humoral immune responses than men, and therefore are less susceptible to bacterial, fungal, parasitic and viral infections <sup><xref ref-type="bibr" rid="B39">39</xref></sup> .</p>
			<p>When it comes to hormonal differences, sex steroids, including testosterone, estrogen and progesterone are potent regulators of immune and inflammatory regulatory responses. Estrogen in women can have immune-boosting effects while testosterone secreted by testicles can have immunosuppressive ones <sup><xref ref-type="bibr" rid="B40">40</xref> , <xref ref-type="bibr" rid="B41">41</xref></sup> . Testosterone can also predispose men to COVID-19 infection by means of co-regulation of the expression of the angiotensin-converting enzyme 2, which may facilitate the entry of virus in cells, thus increasing the number of infected men and the disease severity <sup><xref ref-type="bibr" rid="B42">42</xref></sup> .</p>
			<p>When analyzing the age of death in men and women, it can be noticed that male individuals have a lower mean age than females. A study that investigated the immune response to SARS-CoV-2 infection showed that male patients have a high level of interleukin 18 (IL-18) with a more robust induction of non-classical monocytes, while women have a more robust activation of T cells than men during infection. A low correlation between the patients´ age was associated with a worse prognosis in men than women <sup><xref ref-type="bibr" rid="B43">43</xref></sup> , which may also explain the higher frequency of deaths in men at an earlier age. It is also important to note that many factors can accelerate the individual’s biological age, including diet, physical exercise, habits and some comorbidities <sup><xref ref-type="bibr" rid="B44">44</xref></sup> .</p>
			<p>Studies analyzing COVID-19 clinical and epidemiological data suggest that some medical conditions increase the risk of infections with worsening lung injury and death. The most common medical conditions are hypertension, cardiovascular diseases and diabetes <sup><xref ref-type="bibr" rid="B45">45</xref></sup> , in line with our study in which the majority of patients who died presented these medical conditions. Our study shows that the mean age of those from the group with no medical condition who died is lower than those from the group with at least one medical condition who died. In addition, women, on average, have more medical conditions than men.</p>
			<p>It is well established that the virus uses angiotensin-converting enzyme 2 (ACE2) receptors, which are on the surface of host cells, to enter the cell. Several comorbidities are associated with this receptor. Hypertensive patients often use ACE2 inhibitors and angiotensin receptor blockers in their treatments. These inhibitors increase the expression of the ACE2 receptor, leading to an increased susceptibility to SARS-CoV-2 infection <sup><xref ref-type="bibr" rid="B44">44</xref></sup> . This increase in the expression of recipient cells in the lungs raises the chances of severe lung injury and respiratory failure <sup><xref ref-type="bibr" rid="B45">45</xref></sup> . When it comes to cardiac patients, there is a high risk due to the presence of ACE2 receptors in the cardiac muscles, increasing the occurrence of acute coronary syndrome that can lead to myocardial injury or infarction. An increase in inflammatory cytokines in COVID-19 can lead to ischemia and thrombosis <sup><xref ref-type="bibr" rid="B46">46</xref></sup> . In relation to diabetes, there is a protein called furin that is expressed at high levels in patients with this disease. The SARS-CoV-2 spike protein (S) is activated by increased levels of furin. This pre-activation of the protein S allows the entry of the virus into the cell by the ACE2 receptors, which can be life-threatening to diabetic patients <sup><xref ref-type="bibr" rid="B45">45</xref></sup> .</p>
		</sec>
		<sec sec-type="conclusions">
			<title>CONCLUSIONS</title>
			<p>Finally, as we already know, the COVID-19 pandemic has brought relevant impacts on people’s health and on the mobility dynamics of populations. In Uberaba, the epidemiological characteristics of the pandemic showed a total of more than 17,000 reported cases and more than 400 deaths recorded in a year of the pandemic. The beginning of the year 2021 contributed with many cases and deaths and this increase coincided with the emergence of new variants. The patterns of incidence, age group and biological sex found in this study are similar in different regions of the country and the world. Young people are more affected by the disease; however, older adults show higher lethality rates. Factors such as lifestyle and prevalence of medical conditions are associated with the results and conclusions found.</p>
			<p>The analysis of the epidemiological characteristics of individuals affected by the COVID-19 is important so that all branches of the government can determine actions and measures in favor of public health. The dissemination of the epidemiological characteristics and its analysis also serve to alert the population of their conduct in the midst of an unprecedented pandemic like this. The recent vaccination of the population should not be used as a relief to reduce care and prevention against the virus. New variants are spreading faster than the December 2019 Wuhan version, which makes the coronavirus epidemiological surveillance permanent.</p>
			<p>Vaccination in the city of Uberaba began on January 20th with health professionals. Until the period studied on March 17, 2021, only the elderly over 85 years old had received the doses. Within the period, it was not possible to affirm a decrease in the mortality rate of the elderly.</p>
			<p>We must make sure we use those tools effectively, which means using them in all countries to protect the most at-risk groups. That’s the best way to save lives, end the pandemic, restore confidence and reboot the global economy. But we’re making progress <sup><xref ref-type="bibr" rid="B47">47</xref></sup> .</p>
			<p>
				<fig id="f05">
					<label>Figure 5</label>
					<caption>
						<title>Most frequent medical conditions among the 424 recorded deaths from COVID-19 in the city of Uberaba, MG, Brazil, during one year of the pandemic, from March 18, 2020, to March 17, 2021.</title>
					</caption>
					<graphic xlink:href="f5.jpg"/>
					<attrib>Source: Elaborated by the authors, 2021.</attrib>
				</fig>
			</p>
		</sec>
	</body>
	<back>
		<ack>
			<title>Acknowledgement</title>
			<p>The authors thank the Municipal Health Department from the Uberaba city hall, for the support and data sharing, and translator Maria Teresa Marques Santos, from the International Cooperation Advisory (UFTM). Financial support was provided in part by the Brazilian agencies <italic>Fundação de Amparo à Pesquisa do Estado de Minas Gerais</italic> (FAPEMIG, APQ-00941-14), <italic>Conselho Nacional de Desenvolvimento Científico e Tecnológico</italic> (CNPq, 438316/2018-5 and 312328/2019-2) and also by the <italic>Universidade Federal do Triângulo Mineiro</italic> (UFTM), with the Call for Researcher’s Financial Support (PROPPG/UFTM No. 30/2018).</p>
		</ack>
		<ref-list>
			<title>REFERENCES</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS et al. Coronavirus disease 2019: COVID-19. Clin Microbiol Rev. 2020;33(4):1-40. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CMR.00028-20">https://doi.org/10.1128/CMR.00028-20</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dhama</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Khan</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tiwari</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Sircar</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Bhat</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Malik</surname>
							<given-names>YS</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Coronavirus disease 2019: COVID-19</article-title>
					<source>Clin Microbiol Rev</source>
					<year>2020</year>
					<volume>33</volume>
					<issue>4</issue>
					<fpage>1</fpage>
					<lpage>40</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/CMR.00028-20">https://doi.org/10.1128/CMR.00028-20</ext-link>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>Kadam SB, Sukhramani GS, Bishnoi P, Pable AA, Barvkar VT. SARS-CoV-2, the pandemic coronavirus: molecular and structural insights. J Basic Microbiol. 2021;61(3):180-202. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jobm.202000537">https://doi.org/10.1002/jobm.202000537</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kadam</surname>
							<given-names>SB</given-names>
						</name>
						<name>
							<surname>Sukhramani</surname>
							<given-names>GS</given-names>
						</name>
						<name>
							<surname>Bishnoi</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Pable</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Barvkar</surname>
							<given-names>VT</given-names>
						</name>
					</person-group>
					<article-title>SARS-CoV-2, the pandemic coronavirus: molecular and structural insights</article-title>
					<source>J Basic Microbiol</source>
					<year>2021</year>
					<volume>61</volume>
					<issue>3</issue>
					<fpage>180</fpage>
					<lpage>202</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jobm.202000537">https://doi.org/10.1002/jobm.202000537</ext-link>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>Bhat EA, Khan J, Sajjad N, Ali A, Aldakeel FM, Mateen A et al. SARS-CoV-2: insight in genome structure, pathogenesis and viral receptor binding analysis - an updated review. Int Immunopharmacol. 2021;95:1-9. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.intimp.2021.107493">https://doi.org/10.1016/j.intimp.2021.107493</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bhat</surname>
							<given-names>EA</given-names>
						</name>
						<name>
							<surname>Khan</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Sajjad</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Ali</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Aldakeel</surname>
							<given-names>FM</given-names>
						</name>
						<name>
							<surname>Mateen</surname>
							<given-names>A</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>SARS-CoV-2: insight in genome structure, pathogenesis and viral receptor binding analysis - an updated review</article-title>
					<source>Int Immunopharmacol</source>
					<year>2021</year>
					<volume>95</volume>
					<fpage>1</fpage>
					<lpage>9</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.intimp.2021.107493">https://doi.org/10.1016/j.intimp.2021.107493</ext-link>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>Freitas FC, Ferreira PHB, Favaro DC, Oliveira RJ. Shedding light on the inhibitory mechanisms of SARS-CoV-1/CoV-2 spike proteins by ACE2-designed peptides. J Chem Inf Model. 2021;61(3):1226-43. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/acs.jcim.0c01320">https://doi.org/10.1021/acs.jcim.0c01320</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Freitas</surname>
							<given-names>FC</given-names>
						</name>
						<name>
							<surname>Ferreira</surname>
							<given-names>PHB</given-names>
						</name>
						<name>
							<surname>Favaro</surname>
							<given-names>DC</given-names>
						</name>
						<name>
							<surname>Oliveira</surname>
							<given-names>RJ</given-names>
						</name>
					</person-group>
					<article-title>Shedding light on the inhibitory mechanisms of SARS-CoV-1/CoV-2 spike proteins by ACE2-designed peptides</article-title>
					<source>J Chem Inf Model</source>
					<year>2021</year>
					<volume>61</volume>
					<issue>3</issue>
					<fpage>1226</fpage>
					<lpage>1243</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1021/acs.jcim.0c01320">https://doi.org/10.1021/acs.jcim.0c01320</ext-link>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>World Health Organization – WHO. Brazil. Geneva: World Health Organization; 2021[acess Feb 19, 2021]. Available at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/eportuguese/countries/bra/pt">https://www.who.int/eportuguese/countries/bra/pt</ext-link>
				</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="author">
						<collab>World Health Organization – WHO</collab>
					</person-group>
					<source>Brazil</source>
					<publisher-loc>Geneva</publisher-loc>
					<publisher-name>World Health Organization</publisher-name>
					<year>2021</year>
					<date-in-citation content-type="cited-date">acess Feb 19, 2021</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://www.who.int/eportuguese/countries/bra/pt">https://www.who.int/eportuguese/countries/bra/pt</ext-link>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>Ministério da Saúde (BR). Painel de casos de doenças pelo coronavírus 2019 (COVID-19) no Brasil. Brasília: Ministério da Saúde; 2020 [acess Feb 19, 2021]. Available at: <ext-link ext-link-type="uri" xlink:href="https://covid.saude.gov.br/">https://covid.saude.gov.br/</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Ministério da Saúde (BR)</collab>
					</person-group>
					<source>Painel de casos de doenças pelo coronavírus 2019 (COVID-19) no Brasil</source>
					<publisher-loc>Brasília</publisher-loc>
					<publisher-name>Ministério da Saúde</publisher-name>
					<year>2020</year>
					<date-in-citation content-type="access-date">acess Feb 19, 2021</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://covid.saude.gov.br/">https://covid.saude.gov.br/</ext-link>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>Souza WM, Buss LF, Candido DS, Carrera JP, LI S, Zarebski AE et al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat Hum Behav. 2020;4(8): 856-65. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41562-020-0928-4">https://doi.org/10.1038/s41562-020-0928-4</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Souza</surname>
							<given-names>WM</given-names>
						</name>
						<name>
							<surname>Buss</surname>
							<given-names>LF</given-names>
						</name>
						<name>
							<surname>Candido</surname>
							<given-names>DS</given-names>
						</name>
						<name>
							<surname>Carrera</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>LI</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Zarebski</surname>
							<given-names>AE</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil</article-title>
					<source>Nat Hum Behav</source>
					<year>2020</year>
					<volume>4</volume>
					<issue>8</issue>
					<fpage>856</fpage>
					<lpage>865</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41562-020-0928-4">https://doi.org/10.1038/s41562-020-0928-4</ext-link>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>Gouveia GPM, Gouveia SSV, Vasconcelos SS, Silva ESM, Medeiros RG, Silva RL. Incidência e letalidade da COVID-19 no Ceará. Cad ESP. 2020;14(1):10-6.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gouveia</surname>
							<given-names>GPM</given-names>
						</name>
						<name>
							<surname>Gouveia</surname>
							<given-names>SSV</given-names>
						</name>
						<name>
							<surname>Vasconcelos</surname>
							<given-names>SS</given-names>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>ESM</given-names>
						</name>
						<name>
							<surname>Medeiros</surname>
							<given-names>RG</given-names>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>RL</given-names>
						</name>
					</person-group>
					<article-title>Incidência e letalidade da COVID-19 no Ceará</article-title>
					<source>Cad ESP</source>
					<year>2020</year>
					<volume>14</volume>
					<issue>1</issue>
					<fpage>10</fpage>
					<lpage>16</lpage>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>Romero JAR, Silva FAM. Relação entre as condições socioeconômicas e a incidência da pandemia da COVID-19 nos municípios do Ceará. Bol Conjunt. 2020;3(7):85-95. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.3923443">https://doi.org/10.5281/zenodo.3923443</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Romero</surname>
							<given-names>JAR</given-names>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>FAM</given-names>
						</name>
					</person-group>
					<article-title>Relação entre as condições socioeconômicas e a incidência da pandemia da COVID-19 nos municípios do Ceará</article-title>
					<source>Bol Conjunt</source>
					<year>2020</year>
					<volume>3</volume>
					<issue>7</issue>
					<fpage>85</fpage>
					<lpage>95</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.3923443">https://doi.org/10.5281/zenodo.3923443</ext-link>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>Senhoras EM, Gomes ML. COVID-19 nos municípios de Roraima. Bol Conjunt. 2020;3(9):139-49. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.4036180">https://doi.org/10.5281/zenodo.4036180</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Senhoras</surname>
							<given-names>EM</given-names>
						</name>
						<name>
							<surname>Gomes</surname>
							<given-names>ML</given-names>
						</name>
					</person-group>
					<article-title>COVID-19 nos municípios de Roraima</article-title>
					<source>Bol Conjunt</source>
					<year>2020</year>
					<volume>3</volume>
					<issue>9</issue>
					<fpage>139</fpage>
					<lpage>149</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.4036180">https://doi.org/10.5281/zenodo.4036180</ext-link>
				</element-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation>Paiva CI, Nasr AMLF, Magato DS, Ditterich RG, Guimarães RRM, Piler RA et al. Perfil epidemiológico da COVID-19 no estado do Paraná. Rev Saúde Pública Paraná. 2020;3(suppl.1):39-61. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.32811/25954482-2020v3sup1p39">https://doi.org/10.32811/25954482-2020v3sup1p39</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Paiva</surname>
							<given-names>CI</given-names>
						</name>
						<name>
							<surname>Nasr</surname>
							<given-names>AMLF</given-names>
						</name>
						<name>
							<surname>Magato</surname>
							<given-names>DS</given-names>
						</name>
						<name>
							<surname>Ditterich</surname>
							<given-names>RG</given-names>
						</name>
						<name>
							<surname>Guimarães</surname>
							<given-names>RRM</given-names>
						</name>
						<name>
							<surname>Piler</surname>
							<given-names>RA</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Perfil epidemiológico da COVID-19 no estado do Paraná</article-title>
					<source>Rev Saúde Pública Paraná</source>
					<year>2020</year>
					<volume>3</volume>
					<supplement>suppl.1</supplement>
					<fpage>39</fpage>
					<lpage>61</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.32811/25954482-2020v3sup1p39">https://doi.org/10.32811/25954482-2020v3sup1p39</ext-link>
				</element-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation>Souza ALT, Gusmão JL, Simas JMM, Simas PVM, Ikeda AC. Análise do perfil epidemiológico dos casos confirmados de COVID-19 no Vale do Ribeira, São Paulo, Brasil. Rev Pre Infec Saúde. 2020;6:1-12. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.26694/repis.v6i0.11105">https://doi.org/10.26694/repis.v6i0.11105</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Souza</surname>
							<given-names>ALT</given-names>
						</name>
						<name>
							<surname>Gusmão</surname>
							<given-names>JL</given-names>
						</name>
						<name>
							<surname>Simas</surname>
							<given-names>JMM</given-names>
						</name>
						<name>
							<surname>Simas</surname>
							<given-names>PVM</given-names>
						</name>
						<name>
							<surname>Ikeda</surname>
							<given-names>AC</given-names>
						</name>
					</person-group>
					<article-title>Análise do perfil epidemiológico dos casos confirmados de COVID-19 no Vale do Ribeira, São Paulo, Brasil</article-title>
					<source>Rev Pre Infec Saúde</source>
					<year>2020</year>
					<volume>6</volume>
					<fpage>1</fpage>
					<lpage>12</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.26694/repis.v6i0.11105">https://doi.org/10.26694/repis.v6i0.11105</ext-link>
				</element-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation>Silva, AW, Cunha AA, Alves GC, Corona RA, Dias CAGM, Nassiri R et al. Perfil epidemiológico e determinante social do COVID-19 em Macapá, Amapá, Amazônia, Brasil. Rev Cient Multid Núcleo Conhec. 2020;4(4):5-27. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.32749/nucleodoconhecimento.com.br/saude/covid-19-em-macapa">https://doi.org/10.32749/nucleodoconhecimento.com.br/saude/covid-19-em-macapa</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Silva</surname>
							<given-names>AW</given-names>
						</name>
						<name>
							<surname>Cunha</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Alves</surname>
							<given-names>GC</given-names>
						</name>
						<name>
							<surname>Corona</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Dias</surname>
							<given-names>CAGM</given-names>
						</name>
						<name>
							<surname>Nassiri</surname>
							<given-names>R</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Perfil epidemiológico e determinante social do COVID-19 em Macapá, Amapá, Amazônia, Brasil</article-title>
					<source>Rev Cient Multid Núcleo Conhec</source>
					<year>2020</year>
					<volume>4</volume>
					<issue>4</issue>
					<fpage>5</fpage>
					<lpage>27</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.32749/nucleodoconhecimento.com.br/saude/covid-19-em-macapa">https://doi.org/10.32749/nucleodoconhecimento.com.br/saude/covid-19-em-macapa</ext-link>
				</element-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation>Lopes LFD, Faria RM, Lima MP, Kirchhof RS, Almeida DM, Moura GL. Descrição do perfil epidemiológico da COVID-19 na região sul do Brasil. Hygeia. 2020;16:188-98. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.14393/Hygeia16054772">https://doi.org/10.14393/Hygeia16054772</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lopes</surname>
							<given-names>LFD</given-names>
						</name>
						<name>
							<surname>Faria</surname>
							<given-names>RM</given-names>
						</name>
						<name>
							<surname>Lima</surname>
							<given-names>MP</given-names>
						</name>
						<name>
							<surname>Kirchhof</surname>
							<given-names>RS</given-names>
						</name>
						<name>
							<surname>Almeida</surname>
							<given-names>DM</given-names>
						</name>
						<name>
							<surname>Moura</surname>
							<given-names>GL</given-names>
						</name>
					</person-group>
					<article-title>Descrição do perfil epidemiológico da COVID-19 na região sul do Brasil</article-title>
					<source>Hygeia</source>
					<year>2020</year>
					<volume>16</volume>
					<fpage>188</fpage>
					<lpage>198</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.14393/Hygeia16054772">https://doi.org/10.14393/Hygeia16054772</ext-link>
				</element-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation>Rosa MFP, Silva WNT, Carvalho WRG, Oliveira SV. Epidemiologia da COVID-19 em Uberlândia (MG): análise preliminar do impacto do grau de abertura comercial. J Health NPEPS. 2020;5(2):20-41.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Rosa</surname>
							<given-names>MFP</given-names>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>WNT</given-names>
						</name>
						<name>
							<surname>Carvalho</surname>
							<given-names>WRG</given-names>
						</name>
						<name>
							<surname>Oliveira</surname>
							<given-names>SV</given-names>
						</name>
					</person-group>
					<article-title>Epidemiologia da COVID-19 em Uberlândia (MG): análise preliminar do impacto do grau de abertura comercial</article-title>
					<source>J Health NPEPS</source>
					<year>2020</year>
					<volume>5</volume>
					<issue>2</issue>
					<fpage>20</fpage>
					<lpage>41</lpage>
				</element-citation>
			</ref>
			<ref id="B16">
				<label>16</label>
				<mixed-citation>Silveira CR, Monteiro EM, Bicalho EAG, Vieira ALS. Incidência e prevalência dos casos notificados de COVID-19 no município de Patos de Minas - MG dentre os meses de abril de 2020 a abril de 2021. Sci Gen. 2021;2(2):116-29.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Silveira</surname>
							<given-names>CR</given-names>
						</name>
						<name>
							<surname>Monteiro</surname>
							<given-names>EM</given-names>
						</name>
						<name>
							<surname>Bicalho</surname>
							<given-names>EAG</given-names>
						</name>
						<name>
							<surname>Vieira</surname>
							<given-names>ALS</given-names>
						</name>
					</person-group>
					<article-title>Incidência e prevalência dos casos notificados de COVID-19 no município de Patos de Minas - MG dentre os meses de abril de 2020 a abril de 2021</article-title>
					<source>Sci Gen</source>
					<year>2021</year>
					<volume>2</volume>
					<issue>2</issue>
					<fpage>116</fpage>
					<lpage>129</lpage>
				</element-citation>
			</ref>
			<ref id="B17">
				<label>17</label>
				<mixed-citation>Fortuna DBS, Fortuna JL. Perfil epidemiológico dos casos de COVID-19 no município de Teixeira de Freitas-BA. Braz J Develop. 2020;6(10):76374-92. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.34117/bjdv6n10-166">https://doi.org/10.34117/bjdv6n10-166</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fortuna</surname>
							<given-names>DBS</given-names>
						</name>
						<name>
							<surname>Fortuna</surname>
							<given-names>JL</given-names>
						</name>
					</person-group>
					<article-title>Perfil epidemiológico dos casos de COVID-19 no município de Teixeira de Freitas-BA</article-title>
					<source>Braz J Develop</source>
					<year>2020</year>
					<volume>6</volume>
					<issue>10</issue>
					<fpage>76374</fpage>
					<lpage>76392</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.34117/bjdv6n10-166">https://doi.org/10.34117/bjdv6n10-166</ext-link>
				</element-citation>
			</ref>
			<ref id="B18">
				<label>18</label>
				<mixed-citation>Instituto Brasileiro de Geografia e Estatística – IBGE. População estimada (2020). Rio de Janeiro: Instituto Brasileiro de Geografia e Estatística; 2021[acces May 5, 2021]. Available at: <ext-link ext-link-type="uri" xlink:href="https://cidades.ibge.gov.br/brasil/mg/uberaba/panorama">https://cidades.ibge.gov.br/brasil/mg/uberaba/panorama</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Instituto Brasileiro de Geografia e Estatística – IBGE</collab>
					</person-group>
					<source>População estimada (2020)</source>
					<publisher-loc>Rio de Janeiro</publisher-loc>
					<publisher-name>Instituto Brasileiro de Geografia e Estatística</publisher-name>
					<year>2021</year>
					<date-in-citation content-type="access-date">acces May 5, 2021</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://cidades.ibge.gov.br/brasil/mg/uberaba/panorama">https://cidades.ibge.gov.br/brasil/mg/uberaba/panorama</ext-link>
				</element-citation>
			</ref>
			<ref id="B19">
				<label>19</label>
				<mixed-citation>Silva TA, Maldonado M. Avaliação do uso de leitos de UTI de COVID-19 em Uberaba por meio da teoria de filas. Rev Eletron Mat. 2021;7(2):1-16. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.35819/remat2021v7i2id5123">https://doi.org/10.35819/remat2021v7i2id5123</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Silva</surname>
							<given-names>TA</given-names>
						</name>
						<name>
							<surname>Maldonado</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Avaliação do uso de leitos de UTI de COVID-19 em Uberaba por meio da teoria de filas</article-title>
					<source>Rev Eletron Mat</source>
					<year>2021</year>
					<volume>7</volume>
					<issue>2</issue>
					<fpage>1</fpage>
					<lpage>16</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.35819/remat2021v7i2id5123">https://doi.org/10.35819/remat2021v7i2id5123</ext-link>
				</element-citation>
			</ref>
			<ref id="B20">
				<label>20</label>
				<mixed-citation>Universidade Federal do Triângulo Mineiro – UFTM. Observatório COVID-19 Uberaba. Uberaba: Universidade Federal do Triângulo Mineiro; 2020[acess Feb 19, 2021]. Available at: <ext-link ext-link-type="uri" xlink:href="https://coviduberaba.github.io">https://coviduberaba.github.io</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Universidade Federal do Triângulo Mineiro – UFTM</collab>
					</person-group>
					<source>Observatório COVID-19 Uberaba</source>
					<publisher-loc>Uberaba</publisher-loc>
					<publisher-name>Universidade Federal do Triângulo Mineiro</publisher-name>
					<year>2020</year>
					<date-in-citation content-type="access-date">acess Feb 19, 2021</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://coviduberaba.github.io">https://coviduberaba.github.io</ext-link>
				</element-citation>
			</ref>
			<ref id="B21">
				<label>21</label>
				<mixed-citation>Orellana JDY, Marrero L, Horta BL. Letalidade hospitalar por COVID-19 em quatro capitais brasileiras e sua possível relação temporal com a variante Gama, 2020-2021. Epidemiol Serv Saúde. 2021;30(4):1-12. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S1679-49742021000400024">https://doi.org/10.1590/S1679-49742021000400024</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Orellana</surname>
							<given-names>JDY</given-names>
						</name>
						<name>
							<surname>Marrero</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Horta</surname>
							<given-names>BL</given-names>
						</name>
					</person-group>
					<article-title>Letalidade hospitalar por COVID-19 em quatro capitais brasileiras e sua possível relação temporal com a variante Gama, 2020-2021</article-title>
					<source>Epidemiol Serv Saúde</source>
					<year>2021</year>
					<volume>30</volume>
					<issue>4</issue>
					<fpage>1</fpage>
					<lpage>12</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S1679-49742021000400024">https://doi.org/10.1590/S1679-49742021000400024</ext-link>
				</element-citation>
			</ref>
			<ref id="B22">
				<label>22</label>
				<mixed-citation>Khan M, Khan H, Khan S, Nawaz M. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period. J Med Microbio. 2020;69(8):1114-23. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1099/jmm.0.001231">https://doi.org/10.1099/jmm.0.001231</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Khan</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Khan</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Khan</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Nawaz</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period</article-title>
					<source>J Med Microbio</source>
					<year>2020</year>
					<volume>69</volume>
					<issue>8</issue>
					<fpage>1114</fpage>
					<lpage>1123</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1099/jmm.0.001231">https://doi.org/10.1099/jmm.0.001231</ext-link>
				</element-citation>
			</ref>
			<ref id="B23">
				<label>23</label>
				<mixed-citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736 (20)30183-5">https://doi.org/10.1016/S0140-6736 (20)30183-5</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Huang</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Wang</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Li</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Ren</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Zhao</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Hu</surname>
							<given-names>Y</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>
					<source>Lancet</source>
					<year>2020</year>
					<volume>395</volume>
					<issue>10223</issue>
					<fpage>497</fpage>
					<lpage>506</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736 (20)30183-5">https://doi.org/10.1016/S0140-6736 (20)30183-5</ext-link>
				</element-citation>
			</ref>
			<ref id="B24">
				<label>24</label>
				<mixed-citation>Department of Health (AU). Epidemiology report 30: fortnightly reporting period ending 22 November 2020: communicable diseases intelligence. Camberra: Department of Health; 2020. Available at: www1.health.gov.au</mixed-citation>
				<element-citation publication-type="webpage">
					<person-group person-group-type="author">
						<collab>Department of Health (AU)</collab>
					</person-group>
					<source>Epidemiology report 30: fortnightly reporting period ending 22 November 2020: communicable diseases intelligence</source>
					<publisher-loc>Camberra</publisher-loc>
					<publisher-name>Department of Health</publisher-name>
					<year>2020</year>
					<ext-link ext-link-type="uri" xlink:href="http://www1.health.gov.au">www1.health.gov.au</ext-link>
				</element-citation>
			</ref>
			<ref id="B25">
				<label>25</label>
				<mixed-citation>Silva AWC, Cunha AA, Alves GC, Corona RA, Dias CAGM, Nassiri R et al. Caracterização clínica e epidemiologia de 1560 casos de COVID-19 em Macapá/AP, extremo norte do Brasil. Res Soc Dev. 2020;9(8):1-20. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.33448/rsd-v9i8.5499">https://doi.org/10.33448/rsd-v9i8.5499</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Silva</surname>
							<given-names>AWC</given-names>
						</name>
						<name>
							<surname>Cunha</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Alves</surname>
							<given-names>GC</given-names>
						</name>
						<name>
							<surname>Corona</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Dias</surname>
							<given-names>CAGM</given-names>
						</name>
						<name>
							<surname>Nassiri</surname>
							<given-names>R</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Caracterização clínica e epidemiologia de 1560 casos de COVID-19 em Macapá/AP, extremo norte do Brasil</article-title>
					<source>Res Soc Dev</source>
					<year>2020</year>
					<volume>9</volume>
					<issue>8</issue>
					<fpage>1</fpage>
					<lpage>20</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.33448/rsd-v9i8.5499">https://doi.org/10.33448/rsd-v9i8.5499</ext-link>
				</element-citation>
			</ref>
			<ref id="B26">
				<label>26</label>
				<mixed-citation>Moura PH, Luz RA, Ga MJP, Klokner S, Torrico G, Knapi KJ et al. Perfil epidemiológico da COVID-19 em Santa Catarina. Rev Interdiscip Estud Saúde. 2020;9(1):163-80. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.33362/ries.v9i1.2316">https://doi.org/10.33362/ries.v9i1.2316</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Moura</surname>
							<given-names>PH</given-names>
						</name>
						<name>
							<surname>Luz</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Ga</surname>
							<given-names>MJP</given-names>
						</name>
						<name>
							<surname>Klokner</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Torrico</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Knapi</surname>
							<given-names>KJ</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Perfil epidemiológico da COVID-19 em Santa Catarina</article-title>
					<source>Rev Interdiscip Estud Saúde</source>
					<year>2020</year>
					<volume>9</volume>
					<issue>1</issue>
					<fpage>163</fpage>
					<lpage>180</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.33362/ries.v9i1.2316">https://doi.org/10.33362/ries.v9i1.2316</ext-link>
				</element-citation>
			</ref>
			<ref id="B27">
				<label>27</label>
				<mixed-citation>Cunha AA, Corona RA, Silva DG, Feury AA, Dias CAG, Araujo MHM. Tendência na incidência de acidentes de trajeto em trabalhadores no Brasil entre 2009 e 2016. Rev Bras Med Trab. 2019;17(4):490-8. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5327/Z1679443520190439">https://doi.org/10.5327/Z1679443520190439</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Cunha</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Corona</surname>
							<given-names>RA</given-names>
						</name>
						<name>
							<surname>Silva</surname>
							<given-names>DG</given-names>
						</name>
						<name>
							<surname>Feury</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Dias</surname>
							<given-names>CAG</given-names>
						</name>
						<name>
							<surname>Araujo</surname>
							<given-names>MHM</given-names>
						</name>
					</person-group>
					<article-title>Tendência na incidência de acidentes de trajeto em trabalhadores no Brasil entre 2009 e 2016</article-title>
					<source>Rev Bras Med Trab</source>
					<year>2019</year>
					<volume>17</volume>
					<issue>4</issue>
					<fpage>490</fpage>
					<lpage>498</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5327/Z1679443520190439">https://doi.org/10.5327/Z1679443520190439</ext-link>
				</element-citation>
			</ref>
			<ref id="B28">
				<label>28</label>
				<mixed-citation>Bhopal SS, Bhopal R. Sex differential in COVID-19 mortality varies markedly by age. Lancet. 2020;396(10250):31748-77. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(20)31748-7">https://doi.org/10.1016/S0140-6736 (20)31748-7</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bhopal</surname>
							<given-names>SS</given-names>
						</name>
						<name>
							<surname>Bhopal</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Sex differential in COVID-19 mortality varies markedly by age</article-title>
					<source>Lancet</source>
					<year>2020</year>
					<volume>396</volume>
					<issue>10250</issue>
					<size units="pages">31748-77</size>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(20)31748-7">https://doi.org/10.1016/S0140-6736 (20)31748-7</ext-link>
				</element-citation>
			</ref>
			<ref id="B29">
				<label>29</label>
				<mixed-citation>University College London. African Population and Health Research Center – APHRC. International Center for Research on Women – ICRW. The sex, gender and COVID-19 project. London: University College London; 2021[acess Feb 19, 2021]. Available at: <ext-link ext-link-type="uri" xlink:href="https://globalhealth5050.org/the-sex-gender-and-covid-19-project/">https://globalhealth5050.org/the-sex-gender-and-covid-19-project/</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>University College London</collab>
						<collab>African Population and Health Research Center – APHRC</collab>
						<collab>International Center for Research on Women – ICRW</collab>
					</person-group>
					<source>The sex, gender and COVID-19 project</source>
					<publisher-loc>London</publisher-loc>
					<publisher-name>University College London</publisher-name>
					<year>2021</year>
					<date-in-citation content-type="cited-date">acess Feb 19, 2021</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://globalhealth5050.org/the-sex-gender-and-covid-19-project/">https://globalhealth5050.org/the-sex-gender-and-covid-19-project/</ext-link>
				</element-citation>
			</ref>
			<ref id="B30">
				<label>30</label>
				<mixed-citation>Secretaria de Estado da Saúde de Minas Gerais – SES-MG. Painel de monitoramento de casos: coronavírus. Belo Horizonte: Secretaria de Estado da Saúde de Minas Gerais; 2021[acess Feb 19, 2021]. Available at: <ext-link ext-link-type="uri" xlink:href="https://coronavirus.saude.mg.gov.br/">https://coronavirus.saude.mg.gov.br/</ext-link>
				</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Secretaria de Estado da Saúde de Minas Gerais – SES-MG</collab>
					</person-group>
					<source>Painel de monitoramento de casos: coronavírus</source>
					<publisher-loc>Belo Horizonte</publisher-loc>
					<publisher-name>Secretaria de Estado da Saúde de Minas Gerais</publisher-name>
					<year>2021</year>
					<date-in-citation content-type="access-date">acess Feb 19, 2021</date-in-citation>
					<ext-link ext-link-type="uri" xlink:href="https://coronavirus.saude.mg.gov.br/">https://coronavirus.saude.mg.gov.br/</ext-link>
				</element-citation>
			</ref>
			<ref id="B31">
				<label>31</label>
				<mixed-citation>Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020:42(2):505-14. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11357-020-00186-0">https://doi.org/10.1007/s11357-020-00186-0</ext-link> .</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Nikolich-Zugich</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Knox</surname>
							<given-names>KS</given-names>
						</name>
						<name>
							<surname>Rios</surname>
							<given-names>CT</given-names>
						</name>
						<name>
							<surname>Natt</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Bhattacharya</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Fain</surname>
							<given-names>MJ</given-names>
						</name>
					</person-group>
					<article-title>SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes</article-title>
					<source>Geroscience</source>
					<year>2020</year>
					<volume>42</volume>
					<issue>2</issue>
					<fpage>505</fpage>
					<lpage>514</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s11357-020-00186-0">https://doi.org/10.1007/s11357-020-00186-0</ext-link>
				</element-citation>
			</ref>
			<ref id="B32">
				<label>32</label>
				<mixed-citation>Omarjee L, Perrot F, Meilhac O, Mahe G, Bousquet G, Janin A. Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19. Aging. 2020;12(24): 26263-78. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/aging.202422">https://doi.org/10.18632/aging.202422</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Omarjee</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Perrot</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Meilhac</surname>
							<given-names>O</given-names>
						</name>
						<name>
							<surname>Mahe</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Bousquet</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Janin</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19</article-title>
					<source>Aging</source>
					<year>2020</year>
					<volume>12</volume>
					<issue>24</issue>
					<fpage>26263</fpage>
					<lpage>26278</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.18632/aging.202422">https://doi.org/10.18632/aging.202422</ext-link>
				</element-citation>
			</ref>
			<ref id="B33">
				<label>33</label>
				<mixed-citation>Márquez EJ, Trowbridge J, Kuchel GA, Banchereau J, Ucar D. The lethal sex gap: COVID-19. Immun Ageing. 2020:17:1-8.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Márquez</surname>
							<given-names>EJ</given-names>
						</name>
						<name>
							<surname>Trowbridge</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Kuchel</surname>
							<given-names>GA</given-names>
						</name>
						<name>
							<surname>Banchereau</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ucar</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>The lethal sex gap: COVID-19</article-title>
					<source>Immun Ageing</source>
					<year>2020</year>
					<volume>17</volume>
					<fpage>1</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="B34">
				<label>34</label>
				<mixed-citation>Chen T, Wu D, Chen H, Yan W, Yang D, Chen G et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.m1091">https://doi.org/10.1136/bmj.m1091</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chen</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Wu</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Yan</surname>
							<given-names>W</given-names>
						</name>
						<name>
							<surname>Yang</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>G</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study</article-title>
					<source>BMJ</source>
					<year>2020</year>
					<volume>368</volume>
					<fpage>m1091</fpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/bmj.m1091">https://doi.org/10.1136/bmj.m1091</ext-link>
				</element-citation>
			</ref>
			<ref id="B35">
				<label>35</label>
				<mixed-citation>Dudley JP, Lee NT. Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and Republic of Korea. Clin Infect Dis. 2020;71(15):863-5. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciaa354">https://doi.org/10.1093/cid/ciaa354</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Dudley</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>Lee</surname>
							<given-names>NT</given-names>
						</name>
					</person-group>
					<article-title>Disparities in age-specific morbidity and mortality from SARS-CoV-2 in China and Republic of Korea</article-title>
					<source>Clin Infect Dis</source>
					<year>2020</year>
					<volume>71</volume>
					<issue>15</issue>
					<fpage>863</fpage>
					<lpage>865</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciaa354">https://doi.org/10.1093/cid/ciaa354</ext-link>
				</element-citation>
			</ref>
			<ref id="B36">
				<label>36</label>
				<mixed-citation>Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):1-13. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13293-020-00304-9">https://doi.org/10.1186/s13293-020-00304-9</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gebhard</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Regitz-Zagrosek</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Neuhauser</surname>
							<given-names>HK</given-names>
						</name>
						<name>
							<surname>Morgan</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Klein</surname>
							<given-names>SL</given-names>
						</name>
					</person-group>
					<article-title>Impact of sex and gender on COVID-19 outcomes in Europe</article-title>
					<source>Biol Sex Differ</source>
					<year>2020</year>
					<volume>11</volume>
					<issue>1</issue>
					<fpage>1</fpage>
					<lpage>13</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13293-020-00304-9">https://doi.org/10.1186/s13293-020-00304-9</ext-link>
				</element-citation>
			</ref>
			<ref id="B37">
				<label>37</label>
				<mixed-citation>Haitao T, Vermunt JV, Abeykoon J, Ghamrawi R, Gunaratne M, Jayachandran M et al. COVID-19 and sex differences: mechanisms and biomarkers. Mayo Clin Proc. 2020;95(10):2189-203. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.mayocp.2020.07.024">https://doi.org/10.1016/j.mayocp.2020.07.024</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Haitao</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Vermunt</surname>
							<given-names>JV</given-names>
						</name>
						<name>
							<surname>Abeykoon</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ghamrawi</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Gunaratne</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Jayachandran</surname>
							<given-names>M</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>COVID-19 and sex differences: mechanisms and biomarkers</article-title>
					<source>Mayo Clin Proc</source>
					<year>2020</year>
					<volume>95</volume>
					<issue>10</issue>
					<fpage>2189</fpage>
					<lpage>2203</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.mayocp.2020.07.024">https://doi.org/10.1016/j.mayocp.2020.07.024</ext-link>
				</element-citation>
			</ref>
			<ref id="B38">
				<label>38</label>
				<mixed-citation>Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and sex-specific effects in infectious disease susceptibility. Hum Genomics. 2019;13(1):1-12. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40246-018-0185-z">https://doi.org/10.1186/s40246-018-0185-z</ext-link> .</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Schurz</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Salie</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Tromp</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Hoal</surname>
							<given-names>EG</given-names>
						</name>
						<name>
							<surname>Kinnear</surname>
							<given-names>CJ</given-names>
						</name>
						<name>
							<surname>Möller</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>The X chromosome and sex-specific effects in infectious disease susceptibility</article-title>
					<source>Hum Genomics</source>
					<year>2019</year>
					<volume>13</volume>
					<issue>1</issue>
					<fpage>1</fpage>
					<lpage>12</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s40246-018-0185-z">https://doi.org/10.1186/s40246-018-0185-z</ext-link>
				</element-citation>
			</ref>
			<ref id="B39">
				<label>39</label>
				<mixed-citation>Naqvi S, Bellott DW, Lin KS, Page DC. Conserved microRNA targeting reveals preexisting gene dosage sensitivities that shapedamniote sex chromosome evolution. Genome Res. 2018;28(4):474-83. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/gr.230433.117">https://doi.org/10.1101/gr.230433.117</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Naqvi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Bellott</surname>
							<given-names>DW</given-names>
						</name>
						<name>
							<surname>Lin</surname>
							<given-names>KS</given-names>
						</name>
						<name>
							<surname>Page</surname>
							<given-names>DC</given-names>
						</name>
					</person-group>
					<article-title>Conserved microRNA targeting reveals preexisting gene dosage sensitivities that shapedamniote sex chromosome evolution</article-title>
					<source>Genome Res</source>
					<year>2018</year>
					<volume>28</volume>
					<issue>4</issue>
					<fpage>474</fpage>
					<lpage>483</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/gr.230433.117">https://doi.org/10.1101/gr.230433.117</ext-link>
				</element-citation>
			</ref>
			<ref id="B40">
				<label>40</label>
				<mixed-citation>Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-38. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri.2016.90">https://doi.org/10.1038/nri.2016.90</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Klein</surname>
							<given-names>SL</given-names>
						</name>
						<name>
							<surname>Flanagan</surname>
							<given-names>KL</given-names>
						</name>
					</person-group>
					<article-title>Sex differences in immune responses</article-title>
					<source>Nat Rev Immunol</source>
					<year>2016</year>
					<volume>16</volume>
					<issue>10</issue>
					<fpage>626</fpage>
					<lpage>638</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri.2016.90">https://doi.org/10.1038/nri.2016.90</ext-link>
				</element-citation>
			</ref>
			<ref id="B41">
				<label>41</label>
				<mixed-citation>Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020;11:1-11. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13293-020-00330-7">https://doi.org/10.1186/s13293-020-00330-7</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pradhan</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Olsson</surname>
							<given-names>PE</given-names>
						</name>
					</person-group>
					<article-title>Sex differences in severity and mortality from COVID-19: are males more vulnerable?</article-title>
					<source>Biol Sex Differ</source>
					<year>2020</year>
					<volume>11</volume>
					<fpage>1</fpage>
					<lpage>11</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13293-020-00330-7">https://doi.org/10.1186/s13293-020-00330-7</ext-link>
				</element-citation>
			</ref>
			<ref id="B42">
				<label>42</label>
				<mixed-citation>Giagulli VA, Guastamacchia E, Magrone T, Jirillo E, Lisco G, Pergola G et al. Worse progression of COVID‐19 in men: is testosterone a key factor? Andrology. 2021;9(1):53-64. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/andr.12836">https://doi.org/10.1111/andr.12836</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Giagulli</surname>
							<given-names>VA</given-names>
						</name>
						<name>
							<surname>Guastamacchia</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Magrone</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Jirillo</surname>
							<given-names>E</given-names>
						</name>
						<name>
							<surname>Lisco</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Pergola</surname>
							<given-names>G</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Worse progression of COVID‐19 in men: is testosterone a key factor?</article-title>
					<source>Andrology</source>
					<year>2021</year>
					<volume>9</volume>
					<issue>1</issue>
					<fpage>53</fpage>
					<lpage>64</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/andr.12836">https://doi.org/10.1111/andr.12836</ext-link>
				</element-citation>
			</ref>
			<ref id="B43">
				<label>43</label>
				<mixed-citation>Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J et al. Sex differences in immune responses thatunderlie COVID-19 disease outcomes. Nature. 2020;588(7837):315-20. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41586-020-2700-3">https://doi.org/10.1038/s41586-020-2700-3</ext-link> .</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Takahashi</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Ellingson</surname>
							<given-names>MK</given-names>
						</name>
						<name>
							<surname>Wong</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Israelow</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Lucas</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Klein</surname>
							<given-names>J</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>Sex differences in immune responses thatunderlie COVID-19 disease outcomes</article-title>
					<source>Nature</source>
					<year>2020</year>
					<volume>588</volume>
					<issue>7837</issue>
					<fpage>315</fpage>
					<lpage>320</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41586-020-2700-3">https://doi.org/10.1038/s41586-020-2700-3</ext-link>
				</element-citation>
			</ref>
			<ref id="B44">
				<label>44</label>
				<mixed-citation>Fang L, Karakiukakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):1-1. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S2213-2600 (20)30116-8">https://doi.org/10.1016/S2213-2600 (20)30116-8</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fang</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Karakiukakis</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Roth</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title>
					<source>Lancet Respir Med</source>
					<year>2020</year>
					<volume>8</volume>
					<issue>4</issue>
					<fpage>1</fpage>
					<lpage>1</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S2213-2600 (20)30116-8">https://doi.org/10.1016/S2213-2600 (20)30116-8</ext-link>
				</element-citation>
			</ref>
			<ref id="B45">
				<label>45</label>
				<mixed-citation>Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833-9. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jiph.2020.07.014">https://doi.org/10.1016/j.jiph.2020.07.014</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ejaz</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Alsrhani</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Zafar</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Javed</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Junaid</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Abdalla</surname>
							<given-names>AE</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<article-title>COVID-19 and comorbidities: deleterious impact on infected patients</article-title>
					<source>J Infect Public Health</source>
					<year>2020</year>
					<volume>13</volume>
					<issue>12</issue>
					<fpage>1833</fpage>
					<lpage>1839</lpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jiph.2020.07.014">https://doi.org/10.1016/j.jiph.2020.07.014</ext-link>
				</element-citation>
			</ref>
			<ref id="B46">
				<label>46</label>
				<mixed-citation>Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. Jama Cardiol. 2020;5(7):751-3. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2020.1105">https://doi.org/10.1001/jamacardio.2020.1105</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bonow</surname>
							<given-names>RO</given-names>
						</name>
						<name>
							<surname>Fonarow</surname>
							<given-names>GC</given-names>
						</name>
						<name>
							<surname>O’Gara</surname>
							<given-names>PT</given-names>
						</name>
						<name>
							<surname>Yancy</surname>
							<given-names>CW</given-names>
						</name>
					</person-group>
					<article-title>Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality</article-title>
					<source>Jama Cardiol</source>
					<year>2020</year>
					<volume>5</volume>
					<issue>7</issue>
					<fpage>751</fpage>
					<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1001/jamacardio.2020.1105">https://doi.org/10.1001/jamacardio.2020.1105</ext-link>
				</element-citation>
			</ref>
			<ref id="B47">
				<label>47</label>
				<mixed-citation>Ghebreyesus TA. World Health Organization (WHO) director-general’s opening remarks at Munich security conference, Munich, Germany, 19 February 2021. Geneva: World Health Organization; 2021.</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<name>
							<surname>Ghebreyesus</surname>
							<given-names>TA</given-names>
						</name>
					</person-group>
					<source>World Health Organization (WHO) director-general’s opening remarks at Munich security conference, Munich, Germany, 19 February 2021</source>
					<publisher-loc>Geneva</publisher-loc>
					<publisher-name>World Health Organization</publisher-name>
					<year>2021</year>
				</element-citation>
			</ref>
		</ref-list>
		<fn-group>
			<fn fn-type="other" id="fn">
				<p>Data Availability Statement</p>
				<p>Publicly available datasets were analyzed in this study. Data can be found at <ext-link ext-link-type="uri" xlink:href="https://coronavirus.saude.mg.gov.br/">https://coronavirus.saude.mg.gov.br/</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://coviduberaba.github.io/OneYearData">https://coviduberaba.github.io/OneYearData</ext-link> .</p>
			</fn>
		</fn-group>
	</back>
	<!--<sub-article article-type="translation" id="TRpt" xml:lang="pt">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>ARTIGO</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Um ano da pandemia de COVID-19: características epidemiológicas da COVID-19 na cidade de Uberaba, Minas Gerais, Brasil</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-8822-5508</contrib-id>
					<name>
						<surname>Maldonado</surname>
						<given-names>Michelli</given-names>
					</name>
					<role>Concepção</role>
					<role>planejamento (desenho do estudo)</role>
					<role>aquisição</role>
					<role>análise</role>
					<role>interpretação dos resultados e redação do trabalho</role>
					<xref ref-type="aff" rid="aff1002"><sup>I</sup></xref>
					<xref ref-type="corresp" rid="c01002"><sup>*</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-4860-309X</contrib-id>
					<name>
						<surname>Oliveira</surname>
						<given-names>Ronaldo Junio de</given-names>
					</name>
					<role>Concepção</role>
					<role>planejamento (desenho do estudo)</role>
					<role>e redação do trabalho</role>
					<role>Todos os autores aprovaram a versão final do trabalho</role>
					<xref ref-type="aff" rid="aff2002"><sup>II</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-8223-805X</contrib-id>
					<name>
						<surname>Cintra</surname>
						<given-names>Mariangela Torreglosa Ruiz</given-names>
					</name>
					<role>Concepção</role>
					<role>planejamento (desenho do estudo)</role>
					<role>e redação do trabalho</role>
					<role>Todos os autores aprovaram a versão final do trabalho</role>
					<xref ref-type="aff" rid="aff3002"><sup>III</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1002">
				<label>I</label>
				<country country="BR">Brasil</country>
				<institution content-type="original">Departamento de Matemática, Instituto de Ciências Exatas, Naturais e Educação, Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, MG, Brasil</institution>
			</aff>
			<aff id="aff2002">
				<label>II</label>
				<country country="BR">Brasil</country>
				<institution content-type="original">Laboratório de Biofísica Teórica, Departamento de Física, Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, MG, Brasil</institution>
			</aff>
			<aff id="aff3002">
				<label>III</label>
				<country country="BR">Brasil</country>
				<institution content-type="original">Departamento de Ciências Biológicas, Universidade Federal do Triângulo Mineiro (UFTM), Uberaba, MG, Brasil</institution>
			</aff>
			<author-notes>
				<corresp id="c01002">
					<label>*</label> E-mail: michelli.oliveira@uftm.edu.br </corresp>
				<fn fn-type="conflict">
					<label>Conflito de interesses</label>
					<p>Os autores não têm nenhum conflito de interesse em potencial a declarar, relacionado aos pares e instituições políticas ou financeiras deste estudo.</p>
				</fn>
			</author-notes>
			<abstract>
				<title>RESUMO</title>
				<sec>
					<title>Introdução</title>
					<p> A pandemia do novo coronavírus (COVID-19) é inédita na história humana registrada. Espalhou-se de Wuhan, na China, no início de dezembro de 2019, cruzando todo o planeta e chegando à costa brasileira no mês de fevereiro seguinte. Foi declarada pandemia em 11 de março de 2020, com o primeiro caso registrado na cidade de Uberaba, estado de Minas Gerais, Brasil, em 18 de março de 2020. Desde então, estamos coletando dados e avaliando a evolução dessa fatalidade doença.</p>
				</sec>
				<sec>
					<title>Objetivo</title>
					<p> Neste trabalho, relatamos as características epidemiológicas de um ano da COVID-19 em Uberaba e discutimos suas implicações para o público em geral.</p>
				</sec>
				<sec>
					<title>Método</title>
					<p> Trata-se de um estudo observacional, descritivo, documental e retrospectivo para descrever o perfil epidemiológico dos casos de COVID-19 na cidade de Uberaba no período de 18 de março de 2020 até 17 de março de 2021.</p>
				</sec>
				<sec>
					<title>Resultados</title>
					<p> O estudo mostra que a população jovem em idade ativa é a que mais espalha o vírus, no entanto, os idosos são os que mais sofrem e morrem, com pequenas diferenças em relação ao sexo. Isso está de acordo com os perfis epidemiológicos nacionais e internacionais relatados que mostram uma tendência de mudança das gerações mais jovens a serem cada vez mais ativas na evolução da pandemia. Observamos dois grandes picos nas duas séries temporais epidemiológicas, casos confirmados e óbitos, com média de idade de 41 anos para os casos confirmados e 68 para os óbitos confirmados. Também foi relatado que a taxa de letalidade foi de 2,45%, e 80,00% das mortes confirmadas sofriam de alguma condição de saúde anterior.</p>
				</sec>
				<sec>
					<title>Conclusões</title>
					<p> Nesse sentido, uma vigilância epidemiológica permanente deve ocorrer para orientar as contramedidas de saúde pública. As características epidemiológicas da COVID-19 em Uberaba e análises relacionadas são relatadas no observatório <italic>online</italic> em https://coviduberaba.github.io.</p>
				</sec>
			</abstract>
			<kwd-group xml:lang="pt">
				<kwd>COVID-19</kwd>
				<kwd>Característica Epidemiológicas</kwd>
				<kwd>Vigilância</kwd>
				<kwd>Análise Estatística</kwd>
				<kwd>Coronavírus</kwd>
				<kwd>Saúde Pública</kwd>
			</kwd-group>
		</front-stub>
		<body>
			<sec sec-type="intro">
				<title>INTRODUÇÃO</title>
				<p>Os coronavírus são vírus de RNA de fita positiva que, taxonomicamente, pertencem à família Coronaviridae e à subfamília Coronavirinae, que pode ser dividida em quatro gêneros: Alfa-coronavírus, Betacoronavírus, Gammacoronavírus e Deltacoronavírus. Em sua estrutura, eles são vírus envelopados com um genoma de RNA de fita simples de sentido positivo com formato esférico, oval ou pleomórfico. Os vírus dessa família podem infectar uma grande variedade de hospedeiros, produzindo sintomas e doenças que podem ser leves, moderados ou fatais, como a Síndrome Respiratória Aguda Grave (SARS), causada pelo SARS-CoV, e a Síndrome Respiratória do Oriente Médio (MERS), causada pelo MERS-CoV. O SARS-CoV-2 (<italic>Severe Acute Respiratory Syndrome Coronavirus 2</italic>) pertence ao gênero Betacoronavirus<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup>.</p>
				<p>O SARS-CoV-2, batizado pelo Comitê Internacional de Taxonomia de Vírus (ICTV), contém sequências mais conservadas no quadro aberto de leitura (ORF) 1a/1b. O SARS-CoV-2 infecta humanos e é o agente etiológico da Doença do Coronavírus 2019 (COVID-19)<sup><xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></sup>. A estrutura do SARS-CoV-2 contém um genoma de RNA de fita simples de sentido positivo, embalado no envelope da membrana do vírus. A ORF1a é a ORF mais longa que ocupa quase dois terços do genoma. A ORF1b se sobrepõe à ORF1a seguindo subgRNAs (sgRNA) mais curtos que codificam quatro proteínas estruturais, espícula (S), membrana (M), envelope (E) e nucleocapsídeo (N), além de outras proteínas acessórias. A proteína M promove a curvatura da membrana que ajuda a ligar o nucleocapsídeo. A proteína E desempenha uma função importante na patogênese viral. A proteína N reúne dois domínios capazes de se ligar ao genoma do RNA viral por diferentes mecanismos. A proteína N também interage com a nsp3, ajudando a empacotar e a encapsular a estrutura do genoma dentro dos virions. A superfície do vírus SARS-CoV-2 possui proteínas S que desempenham papéis fundamentais na ligação, fusão e entrada do vírus, estabelecendo um ponto quente para o desenvolvimento de terapias contra o vírus. A proteína S do SARS-CoV-2 inclui o domínio de ligação ao receptor (RBD), conhecido por interagir fortemente com o receptor da enzima conversora de angiotensina 2 (ECA2)<sup><xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup>.</p>
				<p>Em 11 de março de 2020, o surto de COVID-19 foi elevado ao status de pandemia pela Organização Mundial da Saúde (OMS), o que significa que a doença afeta vários países diferentes<sup><xref ref-type="bibr" rid="B5">5</xref></sup>. O primeiro caso foi descrito na cidade chinesa de Wuhan em 1º de dezembro de 2019. No Brasil, o primeiro caso foi relatado em 25 de fevereiro de 2020, na cidade de São Paulo, enquanto o primeiro caso em Uberaba foi relatado em 18 de março de 2020<sup><xref ref-type="bibr" rid="B6">6</xref></sup>A alta transmissão do SARS-CoV-2 causou um número abso- luto de mortes maior do que a combinação das epidemias causadas pelo SARS-CoV e pelo MERS-CoV. Até a conclusão deste trabalho, no final de outubro, o Brasil apresentava uma taxa de letalidade de 2,8%, uma taxa de morbidade de 289 por 100.000 habitantes6. Os dados epidemiológicos de indivíduos infectados pelo vírus, conforme analisados em um estudo brasileiro, mostraram um número de 514.200 pacientes no período de 25 de fevereiro a 31 de maio de 2020. Os pacientes eram predominantemente do sexo masculino, com idade média de 59 anos. A taxa de mortalidade foi de aproximadamente 5,7% e 83,7% desses indivíduos confirmados com a COVID-19 apresentaram pelo menos uma condição médica: 66,5% tinham doença cardiovascular e 54,5% tinham diabetes<sup><xref ref-type="bibr" rid="B7">7</xref></sup>.</p>
				<p>Vários estudos foram realizados no Brasil com o objetivo de avaliar a incidência e a prevalência da COVID-19 em estados como Ceará<sup><xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref></sup>, Roraima<sup><xref ref-type="bibr" rid="B10">10</xref></sup>, Paraná<sup><xref ref-type="bibr" rid="B11">11</xref></sup>, regiões como o Vale do Ribeira<sup><xref ref-type="bibr" rid="B12">12</xref></sup>, Amazônia<sup><xref ref-type="bibr" rid="B13">13</xref></sup>, Sul<sup><xref ref-type="bibr" rid="B14">14</xref></sup> e municípios brasileiros como Uberlândia<sup><xref ref-type="bibr" rid="B15">15</xref></sup> e Patos de Minas, no Estado de Minas Gerais<sup><xref ref-type="bibr" rid="B16">16</xref></sup>, e Teixeira de Freitas na Bahia<sup><xref ref-type="bibr" rid="B17">17</xref></sup>.</p>
				<p>Uberaba, uma cidade do Triângulo Mineiro, tem uma área territorial de 4.539,57 km<sup><xref ref-type="bibr" rid="B2">2</xref></sup> e uma população estimada de 340.277 pessoas<sup><xref ref-type="bibr" rid="B18">18</xref></sup>. As medidas de isolamento na cidade de Uberaba tiveram início em 18 de março de 2020, com a suspensão de serviços cirúrgicos, atendimento em clínicas e outras áreas relacionadas à saúde. Logo em seguida, as medidas de isolamento tomaram proporções maiores, com o fechamento de estabelecimentos comerciais, locais de lazer e restaurantes, deixando abertos apenas os serviços considerados essenciais, como supermercados, farmácias e hospitais. Os estabelecimentos foram autorizados a reabrir com medidas de proteção obrigatórias, como distanciamento social, higiene e uso obrigatório de máscaras em maio de 2020. Até o final de 2020, um decreto impediu o funcionamento de redes de ensino presencial, restaurantes, academias, festas e similares<sup><xref ref-type="bibr" rid="B19">19</xref></sup>.</p>
				<p>Com os contínuos desdobramentos da pandemia, foi criado o Observatório COVID-19 - Uberaba<sup><xref ref-type="bibr" rid="B20">20</xref></sup>, uma iniciativa de pesquisadores da Universidade Federal do Triângulo Mineiro (UFTM) em parceria com a Prefeitura de Uberaba. O grupo apresenta relatórios semanais com informações sobre a epidemiologia da doença, ajudando a fornecer informações seguras à população por meio do site (https://coviduberaba.github.io) e contribuindo para a conscientização sobre a situação.</p>
				<p>Diante disso, este trabalho teve como objetivo traçar um perfil epidemiológico e entender a dinâmica da doença na cidade de Uberaba.</p>
			</sec>
			<sec sec-type="methods">
				<title>MÉTODO</title>
				<sec>
					<title>Região de estudo</title>
					<p>A cidade de Uberaba é um município brasileiro localizado na região do Triângulo Mineiro, no Estado de Minas Gerais (MG). De acordo com o Instituto Brasileiro de Geografia e Estatística (IBGE), a população estimada de Uberaba em 2020 é de 340.277 habitantes, dos quais 48,8% são homens e 51,2% são mulheres<sup><xref ref-type="bibr" rid="B18">18</xref></sup>.</p>
				</sec>
				<sec>
					<title>Coleta de dados</title>
					<p>Trata-se de um estudo observacional, descritivo, documental e retrospectivo para descrever o perfil epidemiológico dos casos de COVID-19 na cidade de Uberaba no período de 18 de março de 2020 a 17 de março de 2021. As variáveis analisadas foram: número de casos e óbitos por semanas epidemiológicas, sexo e faixa etária dos casos confirmados, sexo e faixa etária dos óbitos confirmados e indicação prévia de condições clínicas nos óbitos confirmados. Os dados foram organizados, tabulados e analisados usando o software Microsoft® Excel versão 2000 e o software R-Project 4.0 versão 2016 (https://www.r-project.org).</p>
				</sec>
				<sec>
					<title>Declaração de ética</title>
					<p>Foram seguidos, mantidos e respeitados rigorosos aspectos éticos e profissionais, conforme estabelecido pelo Conselho Nacional de Saúde na Resolução nº 466, de 12 de dezembro de 2012. A resolução recomenda que pesquisas que envolvam apenas dados secundários de domínio público, sem identificação nominal dos participantes da pesquisa, não necessitem de análise pelos Comitês de Ética em Pesquisa.</p>
				</sec>
				<sec>
					<title>Análise estatística</title>
					<p>Os dados foram compilados e tabulados para determinar as frequências simples (n), as frequências relativas (%), as médias e o desvio padrão (±). Os resultados são apresentados em tabelas e gráficos de contingência.</p>
				</sec>
			</sec>
			<sec sec-type="results">
				<title>RESULTADOS</title>
				<p>O estudo apresenta uma análise dos casos notificados de COVID-19 na cidade de Uberaba, estado de MG, Brasil, durante um ano da pandemia. O primeiro caso registrado foi em 18 de março de 2020 e, até 17 de março de 2021, a cidade contabilizava 17.254 casos registrados de pessoas infectadas pelo novo coronavírus. O primeiro pico na cidade ocorreu em 21 de setembro de 2020, com uma média móvel de casos diários de 107 casos. Após essa data, a média móvel de casos diários começou a desacelerar, voltando a bater recordes na segunda onda que começou na primeira quinzena de janeiro de 2021, com 120 casos diários relatados na média móvel e um novo pico em 10 de março de 2021, com uma média móvel de casos diários de 129 casos.</p>
				<p>A <xref ref-type="fig" rid="f01002">Figura 1</xref> mostra a frequência de casos relatados de COVID-19 por semanas epidemiológicas. O primeiro pico ocorreu na semana epidemiológica número 38 (S38) no ano de 2020, com 735 casos, enquanto o segundo pico, no período estudado, foi na S10 no ano de 2021, com 885 casos. Isso representa um aumento de 20,00% dos casos registrados. Além disso, a cidade registrou 9.741 casos no ano de 2020. Até 17 de março de 2021, a cidade já tinha 7.513 casos, o que representa 77,00% do total do ano anterior.</p>
				<p>
					<fig id="f01002">
						<label>Figura 1</label>
						<caption>
							<title>Número total de casos confirmados organizados por semanas epidemiológicas na cidade de Uberaba, estado de Minas Gerais (MG), Brasil, durante um ano da pandemia, de 18 de março de 2020 a 17 de março de 2021.</title>
						</caption>
						<graphic xlink:href="2317-269X-visa-10-02-0023-gf01-pt.tif"/>
						<attrib>Fonte: Elaborado pelos autores, 2021.</attrib>
					</fig>
				</p>
				<p>Considerando a variável sexo, na <xref ref-type="fig" rid="f02002">Figura 2</xref>(a), 51,69% dos casos relatados de COVID-19 eram do sexo feminino, enquanto 48,31% eram do sexo masculino.</p>
				<p>
					<fig id="f02002">
						<label>Figura 2</label>
						<caption>
							<title>Número total de casos confirmados organizados pelos grupos sexo (2a) e sexo (2b) na cidade de Uberaba, estado de Minas Gerais (MG), Brasil, durante um ano da pandemia, de 18 de março de 2020 a 17 de março de 2021.</title>
						</caption>
						<graphic xlink:href="2317-269X-visa-10-02-0023-gf02-pt.tif"/>
						<attrib>Fonte: Elaborado pelos autores, 2021.</attrib>
					</fig>
				</p>
				<p>O grupo feminino era, em média, mais velho (41,64 anos ± 16,97) do que o grupo masculino (40,67 anos ± 16,27). A <xref ref-type="fig" rid="f02002">Figura 2</xref>(b) mostra, em verde, a frequência relativa de casos notificados de COVID-19 por faixa etária na cidade de Uberaba de 18 de março de 2020 a 17 de março de 2021. A faixa etária mais afetada foi a de 30 a 39 anos, com 25,83% do total de casos. A faixa etária de 20 a 49 anos responde por 64,75% dos casos registrados de COVID-19 em Uberaba. A idade média do número total de casos foi de 41 anos ± 16,64.</p>
				<p>As mortes relacionadas à COVID também foram investigadas e podem ser visualizadas na <xref ref-type="fig" rid="f03002">Figura 3</xref> de acordo com as semanas epidemiológicas. O primeiro pico ocorreu em S41 no ano de 2020 com 12 mortes, enquanto o segundo pico apareceu em S11 no ano de 2021 com 38 mortes.</p>
				<p>
					<fig id="f03002">
						<label>Figura 3</label>
						<caption>
							<title>Número total de mortes confirmadas organizadas por semanas epidemiológicas na cidade de Uberaba, estado de Minas Gerais (MG), Brasil, durante um ano da pandemia, de 18 de março de 2020 a 17 de março de 2021.</title>
						</caption>
						<graphic xlink:href="2317-269X-visa-10-02-0023-gf03-pt.tif"/>
						<attrib>Fonte: Elaborado pelos autores, 2021.</attrib>
					</fig>
				</p>
				<p>Isso representa um aumento de 216,00%. O recorde de mortes diárias confirmadas foi registrado em março de 2021, com dez mortes relatadas. A <xref ref-type="fig" rid="f04002">Figura 4</xref>(a) mostra que a idade média das mortes confirmadas foi de 68,85 anos (± 15,68). A <xref ref-type="fig" rid="f04002">Figura 4</xref>(b) mostra a frequência relativa de mortes relatadas de COVID-19 na cidade de Uberaba agrupadas por idade. Até 17 de março, 424 mortes foram registradas, indicando uma taxa de letalidade geral de 2,45%. A idade mínima foi de um ano e a idade máxima foi de 103 anos. 75,00% dos falecidos tinham mais de 59 anos. A <xref ref-type="fig" rid="f04002">Figura 4</xref>(b) indica que a faixa etária que se destaca é a de 70 a 79 anos, 26,18%.</p>
				<p>
					<fig id="f04002">
						<label>Figura 4</label>
						<caption>
							<title>Número total de óbitos confirmados organizados por grupos de idade e gênero na cidade de Uberaba, estado de Minas Gerais (MG), Brasil, durante um ano de pandemia, de 18 de março de 2020 a 17 de março de 2021.</title>
						</caption>
						<graphic xlink:href="2317-269X-visa-10-02-0023-gf04-pt.tif"/>
						<attrib>Fonte: Elaborado pelos autores, 2021.</attrib>
					</fig>
				</p>
				<p>É possível analisar o grau de letalidade do novo coronavírus por faixa etária. A <xref ref-type="fig" rid="f02002">Figura 2</xref>(b), em roxo, também compara mortes confirmadas com casos registrados de COVID-19 por faixa etária da população afetada. A população mais jovem apresenta a maior incidência de casos, mas com uma taxa de letalidade muito baixa. A maior letalidade foi encontrada na faixa etária de 90 anos ou mais, com 34,62% das mortes entre os casos registrados nessa faixa etária, conforme mostrado na <xref ref-type="fig" rid="f04002">Figura 4</xref>(b). A maioria das mortes foi do sexo masculino (57,78%). A taxa de letalidade entre os homens foi de 2,93%, enquanto entre as mulheres foi de 2,00%. As mulheres apresentaram idade média mais alta (71,41 anos ± 15,92) do que os homens (67,00 anos ± 15,30).</p>
				<p>As condições médicas dos falecidos também foram analisadas e organizadas na <xref ref-type="fig" rid="f05002">Figura 5</xref>(a). De acordo com a frequência do diagnóstico, as condições médicas predominantes foram: hipertensão (39,00%), doença cardíaca (21,43%), diabetes (21,43%), obesidade (8,30%) e outras condições médicas (18,15%), conforme indicado na <xref ref-type="fig" rid="f05002">Figura 5</xref>(a). A idade média do grupo sem comorbidades que morreu foi menor (61,90 anos ± 17,01) do que a do grupo que relatou ter condições médicas (70,58 anos ± 14,86).</p>
				<p>
					<fig id="f05002">
						<label>Figura 5</label>
						<caption>
							<title>Condições médicas mais frequentes entre os 424 óbitos registrados por COVID-19 na cidade de Uberaba, MG, Brasil, durante um ano de pandemia, de 18 de março de 2020 a 17 de março de 2021.</title>
						</caption>
						<graphic xlink:href="2317-269X-visa-10-02-0023-gf05-pt.tif"/>
						<attrib>Fonte: Elaborado pelos autores, 2021.</attrib>
					</fig>
				</p>
				<p>A <xref ref-type="fig" rid="f05002">Figura 5</xref>(b) agrupa o número de comorbidades em indivíduos que morreram de coronavírus. Em relação aos 424 óbitos, 85 (20,04%) não indicaram nenhuma comorbidade prévia. Entre eles, 32,94% eram do sexo feminino e 67,05% do sexo masculino.</p>
			</sec>
			<sec sec-type="discussion">
				<title>DISCUSSÃO</title>
				<p>Este estudo traçou o perfil epidemiológico da cidade de Uberaba-MG no primeiro ano da pandemia da COVID-19. Os resultados dessa investigação epidemiológica indicam uma maior envolvimento de mulheres, com idade entre 20 e 49 anos. Com relação aos óbitos, há uma taxa de mortalidade maior em homens, com mais de 60 anos, com histórico de hipertensão, doenças cardíacas, diabetes, obesidade, entre outros.</p>
				<p>Com relação à contaminação, nossos resultados mostram que a faixa etária mais afetada é a de 30 a 39 anos, e o sexo mais afetado - apesar da pequena diferença - é o feminino. Em média, a idade dos indivíduos infectados é de 41 anos e as mulheres eram mais velhas do que os homens. Ou seja, os homens infectados são mais jovens do que as mulheres.</p>
				<p>Com relação às mortes, a ocorrência é mais frequente em indivíduos acima de 60 anos, com pelo menos uma condição médica. A taxa de letalidade dos homens é 1,5 vez maior do que a das mulheres, e os homens eram, em média, mais jovens do que as mulheres. Os homens que morrem de COVID-19 são mais jovens e têm menos condições médicas em comparação com as mulheres.</p>
				<p>Em 17 de março de 2021, a pandemia de COVID-19 em Uberaba resultou em 17.254 casos notificados, com um pico de 129 casos em 10 de março de 2021. Observa-se que o número total de casos em 2021 até 17 de março, em apenas onze semanas, representa mais de 77,00% do total de casos em 2020. O maior pico da segunda onda na cidade de Uberaba ocorreu na semana epidemiológica número 20, em meados de junho, com mais de 1.300 casos por semana<sup><xref ref-type="bibr" rid="B20">20</xref></sup>. A diferença no número total de casos do primeiro pico para o segundo, no período estudado e no restante do ano, é explicada pelas novas variantes que surgiram no país e que contribuíram para o aumento da incidência de casos e óbitos<sup><xref ref-type="bibr" rid="B21">21</xref></sup>. A doença também foi responsável por 424 óbitos na cidade, dos quais 42,60% foram notificados no período estudado em 2021, coincidindo novamente com o surgimento de novas variantes.</p>
				<p>O primeiro pico de casos notificados no Brasil ocorreu em 29 de julho de 2020<sup><xref ref-type="bibr" rid="B6">6</xref></sup>, e uma possível explicação para essa diferença está relacionada ao fato de que a pandemia começou nas capitais brasileiras, principalmente naquelas com aeroportos internacionais. Com base no sequenciamento e na análise de genomas virais, outro estudo brasileiro mostrou que houve mais de 100 entradas internacionais do vírus no Brasil, principalmente de países europeus. Durante o estágio inicial da pandemia, as capitais com aeroportos internacionais sofreram os primeiros picos da doença, que se espalhou progressivamente para regiões do interior, como o Triângulo Mineiro.</p>
				<p>Nosso estudo também revelou que a faixa etária de 20 a 49 anos reunia o maior número de indivíduos contaminados. Em média, eles tinham 41 anos de idade. Esses dados estão de acordo com estudos realizados no Paquistão, onde os indivíduos contaminados tinham, em média, 47 anos de idade, sendo que a faixa etária de 20 a 69 anos apresentou uma frequência maior de infecções<sup><xref ref-type="bibr" rid="B22">22</xref></sup>. Resultados semelhantes foram observados em uma das primeiras descrições das características epidemiológicas em Wuhan, com idade média de 49 anos<sup><xref ref-type="bibr" rid="B23">23</xref></sup> e na Austrália, com idade média de 37 anos<sup><xref ref-type="bibr" rid="B24">24</xref></sup>. Estudos nacionais também chegaram às mesmas conclusões, com o exemplo de Macapá<sup><xref ref-type="bibr" rid="B25">25</xref></sup>, com média de idade de 40 anos, e o estado de Santa Catarina<sup><xref ref-type="bibr" rid="B26">26</xref></sup>, com a mesma faixa etária revelada como a mais afetada.</p>
				<p>Este cenário também pode ser explicado pelos fatores de risco aos quais esse grupo está exposto, como ocupações profissionais, estilo de vida, ausência de comorbidades ou uso de medicamentos, que podem refletir fatores sociais e culturais<sup><xref ref-type="bibr" rid="B27">27</xref></sup>. Possíveis explicações genéticas serão necessárias para completar a interação de idade, sexo e fatores de risco<sup><xref ref-type="bibr" rid="B28">28</xref></sup>.</p>
				<p>Com relação ao sexo biológico dos casos notificados, nosso estudo mostra que, embora sutis, há diferenças tanto nas frequências de homens e mulheres quanto na taxa de incidência entre os sexos. As mulheres se destacam nessa fase do estudo, resultado que difere da investigação que analisa a pan-demia no Brasil e revela que 57,00% dos afetados são homens7. No entanto, a frequência de homens (49,10%) e mulheres (50,90%) infectados é idêntica aos resultados apresentados em janeiro de 2021 no Sudeste Asiático e no Mediterrâneo Ocidental e também está próxima das frequências africanas (47,00% e 53,00%, respectivamente)<sup><xref ref-type="bibr" rid="B29">29</xref></sup>. A análise estatística dos dados confirma que há uma relação entre idade e sexo biológico, e que as mulheres infectadas são mais velhas do que os homens<sup><xref ref-type="bibr" rid="B20">20</xref></sup>.</p>
				<p>Nossos dados revelaram que, até 17 de março de 2021, foram registrados 305 óbitos por COVID-19, indicando uma taxa de letalidade geral de 2,45%. A taxa de mortalidade em Uberaba é maior do que a taxa de mortalidade média no Brasil (2,45, Uberaba, 2,40, Brasil)<sup><xref ref-type="bibr" rid="B6">6</xref></sup>, e a do estado de Minas Gerais - 2,09%, considerando o mesmo período de estudo<sup><xref ref-type="bibr" rid="B30">30</xref></sup>.</p>
				<p>A idade média dos indivíduos que morreram na cidade foi de 71 anos, a maioria deles tinha mais de 60 anos e a categoria de idade com maior letalidade foi a de 90 anos ou mais. Esse padrão etário encontrado em Uberaba está relacionado aos dados encontrados nos EUA, onde 80,00% dos falecidos eram pacientes idosos com 65 anos ou mais, e pacientes com 85 anos ou mais<sup><xref ref-type="bibr" rid="B31">31</xref></sup>. Além disso, em estudos nacionais, como o do estado de Macapá<sup><xref ref-type="bibr" rid="B13">13</xref></sup>, a maior taxa de letalidade foi observada em idosos com mais de 70 anos. Uma das possíveis explicações é que, em geral, as infecções em idosos são atípicas e alguns fatores podem contribuir para a alta incidência de morte, como alterações fisiológicas causadas pelo processo de envelhecimento, condições médicas e uso de vários medicamentos. O avanço da idade, portanto, é considerado o principal fator de risco para as complicações da COVID-19<sup><xref ref-type="bibr" rid="B31">31</xref></sup>. A senescência também afeta as células imunológicas, e as características da imunossenescência são caracterizadas pela diminuição das células T nativas, aumento das células T de memória e resposta deficiente a antígenos recém-encontrados<sup><xref ref-type="bibr" rid="B32">32</xref></sup>.</p>
				<p>Além do fator idade, algumas pesquisas revelam que o sexo biológico pode estar associado ao aumento de mortes por COVID-19<sup><xref ref-type="bibr" rid="B33">33</xref></sup>. Em nosso estudo, a maioria das mortes é do sexo masculino. Investigações realizadas na China, Coreia do Sul, EUA e Itália mostraram uma taxa de mortalidade maior em pacientes do sexo masculino<sup><xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref></sup>. Essa diferença entre os sexos pode ser devida a uma combinação de fatores biológicos, como diferenças na composição cromossômica, nos órgãos reprodutivos e nos hormônios relacionados ao sexo. Fatores específicos de gênero também podem desempenhar um papel, como diferenças comportamentais (hábitos de fumar e beber) e muitas condições médicas que são mais frequentes em homens<sup><xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B36">36</xref></sup>.</p>
				<p>Com relação à diferença cromossômica, as mulheres humanas têm dois cromossomos X, enquanto os homens humanos têm apenas um. Sabe-se que o processo de inativação do X nas mulheres ocorre para que, fisiologicamente, haja compensação de dosagem. Entretanto, 15% a 20% dos genes escapam da inativação em humanos, resultando em um número maior de cópias em mulheres do que em homens<sup><xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref></sup>. Portanto, como o cromossomo X codifica alguns genes relacionados às respostas imunológicas, as mulheres têm um nível mais baixo de carga viral e menos inflamação em comparação com os homens<sup><xref ref-type="bibr" rid="B38">38</xref></sup>. Nossos dados não mostraram diferença entre a contaminação de homens e mulheres, mas está documentado que as mulheres têm respostas imunes inatas e humorais mais fortes do que os homens e, portanto, são menos suscetíveis a infecções bacterianas, fúngicas, parasitárias e virais<sup><xref ref-type="bibr" rid="B39">39</xref></sup>.</p>
				<p>Quando se trata de diferenças hormonais, os esteroides sexuais, incluindo a testosterona, o estrogênio e a progesterona, são reguladores potentes das respostas imunológicas e inflamatórias. O estrogênio nas mulheres pode ter efeitos de reforço imunológico, enquanto a testosterona secretada pelos testículos pode ter efeitos imunossupressores<sup><xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref></sup>. A testosterona também pode predispor os homens à infecção por COVID-19 por meio da co-regulação da expressão da angiotensina-que pode facilitar a entrada do vírus nas células, aumentando assim o número de homens infectados e a gravidade da doença<sup><xref ref-type="bibr" rid="B42">42</xref></sup>.</p>
				<p>Ao analisar a idade de morte em homens e mulheres, nota-se que os indivíduos do sexo masculino têm uma idade média mais baixa do que as mulheres. Um estudo que investigou a resposta imune à infecção por SARS-CoV-2 mostrou que os pacientes do sexo masculino têm um alto nível de interleucina 18 (IL-18) com uma indução mais robusta de monócitos não clássicos, enquanto as mulheres têm uma ativação mais robusta de células T do que os homens durante a infecção. Uma baixa correlação entre a idade dos pacientes foi associada a um pior prognóstico em homens do que em mulheres<sup><xref ref-type="bibr" rid="B43">43</xref></sup>, o que também pode explicar a maior frequência de mortes em homens em uma idade mais precoce. Também é importante observar que muitos fatores podem acelerar a idade biológica do indivíduo, incluindo dieta, exercícios físicos, hábitos e algumas comorbidades<sup><xref ref-type="bibr" rid="B44">44</xref></sup>.</p>
				<p>Estudos que analisam dados clínicos e epidemiológicos da COVID-19 sugerem que algumas condições médicas aumentam o risco de infecções com piora da lesão pulmonar e morte. As condições médicas mais comuns são hipertensão, doenças cardiovasculares e diabetes<sup><xref ref-type="bibr" rid="B45">45</xref></sup>, de acordo com nosso estudo, no qual a maioria dos pacientes que morreram apresentava essas condições médicas. Nosso estudo mostra que a idade média dos pacientes que morreram do grupo sem nenhuma condição médica é menor do que a dos pacientes que morreram do grupo com pelo menos uma condição médica. Além disso, as mulheres, em média, têm mais condições médicas do que os homens.</p>
				<p>Está bem estabelecido que o vírus usa os receptores da enzima conversora de angiotensina 2 (ECA2), que estão na superfície das células hospedeiras, para entrar na célula. Várias comorbidades estão associadas a esse receptor. Os pacientes hipertensos geralmente usam inibidores da ECA2 e bloqueadores do receptor de angiotensina em seus tratamentos.</p>
				<p>Esses inibidores aumentam a expressão do receptor ECA2, levando a uma maior suscetibilidade à infecção por SARS-CoV-2<sup><xref ref-type="bibr" rid="B44">44</xref></sup>. Esse aumento na expressão de células receptoras nos pulmões aumenta as chances de lesão pulmonar grave e insuficiência respiratória<sup><xref ref-type="bibr" rid="B45">45</xref></sup>. Quando se trata de pacientes cardíacos, há um alto risco devido à presença de receptores ECA2 nos músculos cardíacos, aumentando a ocorrência de síndrome coronariana aguda que pode levar a lesão ou infarto do miocárdio. Um aumento das citocinas inflamatórias na COVID-19 pode levar à isquemia e à trombose<sup><xref ref-type="bibr" rid="B46">46</xref></sup>. Em relação ao diabetes, há uma proteína chamada furina que é expressa em altos níveis em pacientes com essa doença. A proteína spike (S) do SARS-CoV-2 é ativada por níveis elevados de furina. Essa pré-ativação da proteína S permite a entrada do vírus na célula pelos receptores ECA2, o que pode ser fatal para os pacientes diabéticos<sup><xref ref-type="bibr" rid="B45">45</xref></sup>.</p>
			</sec>
			<sec sec-type="conclusions">
				<title>CONCLUSÕES</title>
				<p>Por fim, como já sabemos, a pandemia da COVID-19 trouxe impactos relevantes na saúde das pessoas e na dinâmica de mobilidade das populações. Em Uberaba, as características epidemiológicas da pandemia mostraram um total de mais de 17.000 casos notificados e mais de 400 mortes registradas em um ano de pandemia. O início do ano de 2021 contribuiu com muitos casos e mortes e esse aumento coincidiu com o surgimento de novas variantes. Os padrões de incidência, faixa etária e sexo biológico encontrados neste estudo são semelhantes em diferentes regiões do país e do mundo. Os jovens são mais afetados pela doença; entretanto, os adultos mais velhos apresentam taxas de letalidade mais altas. Fatores como estilo de vida e prevalência de condições médicas estão associados aos resultados e conclusões encontrados.</p>
				<p>A análise das características epidemiológicas dos indivíduos afetados pela COVID-19 é importante para que todas as esferas do governo possam determinar ações e medidas em prol da saúde pública. A divulgação das características epidemiológicas e sua análise também servem para alertar a população sobre sua conduta em meio a uma pandemia sem precedentes como essa. A recente vacinação da população não deve ser usada como um alívio para reduzir os cuidados e a prevenção contra o vírus. Novas variantes estão se espalhando mais rapidamente do que a versão de Wuhan de dezembro de 2019, o que torna a vigilância epidemiológica do coronavírus permanente.</p>
				<p>A vacinação na cidade de Uberaba começou no dia 20 de janeiro com os profissionais de saúde. Até o período estudado, em 17 de março de 2021, apenas os idosos acima de 85 anos haviam recebido as doses. No período, não foi possível afirmar uma diminuição na taxa de mortalidade dos idosos.</p>
				<p>Devemos nos certificar de que usamos essas ferramentas de forma eficaz, o que significa usá-las em todos os países para proteger os grupos de maior risco. Essa é a melhor maneira de salvar vidas, acabar com a pandemia, restaurar a confiança e reiniciar a economia global. Mas estamos progredindo<sup><xref ref-type="bibr" rid="B47">47</xref></sup>.</p>
			</sec>
		</body>
		<back>
			<ack>
				<title>Agradecimento</title>
				<p>Os autores agradecem à Secretaria Municipal de Saúde da Prefeitura de Uberaba, pelo apoio e compartilhamento de dados, e à tradutora Maria Teresa Marques Santos, da Assessoria de Cooperação Internacional (UFTM). O apoio financeiro foi fornecido, em parte, pelas agências brasileiras Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG, APQ-00941-14), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, 438316/2018-5 e 312328/2019-2) e também pela Universidade Federal do Triângulo Mineiro (UFTM), com o Edital de Apoio Financeiro ao Pesquisador (PROPPG/UFTM n.º. 30/2018).</p>
			</ack>
			<fn-group>
				<fn fn-type="data-availability" specific-use="data-available">
					<label>Declaração de disponibilidade de dados</label>
					<p>Conjuntos de dados disponíveis publicamente foram analisados neste estudo. Os dados podem ser encontrados em <ext-link ext-link-type="uri" xlink:href="https://coronavirus.saude.mg.gov.br/">https://coronavirus.saude.mg.gov.br/</ext-link> e <ext-link ext-link-type="uri" xlink:href="https://covidu-beraba.github.io/OneYearData">https://covidu-beraba.github.io/OneYearData</ext-link>.</p>
				</fn>
			</fn-group>
		</back>
	</sub-article>-->
</article>